================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
Annual Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
For the Fiscal Year Ended
December 31, 2004 (Commission File No. 0-23047)
SIGA Technologies, Inc.
(Exact name of registrant as specified in its charter)
Delaware 13-3864870
(State or other jurisdiction of (IRS Employer Id. No.)
incorporation or organization)
420 Lexington Avenue, Suite 408 10170
New York, NY (zip code)
(Address of principal executive offices)
Registrant's telephone number, including area code: (212) 672-9100
Securities registered pursuant to Section 12(b) of the Act:
None
(Title of Class)
Securities registered pursuant to Section 12(g) of the Act:
common stock, $.0001 par value
(Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes |X| No |_|.
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. |_|.
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Act). Yes |_| No |X|
The aggregate market value of the voting stock held by non-affiliates of the
registrant, based upon the closing sale price of the common stock on March 28,
2005 as reported on the Nasdaq SmallCap Market was approximately $37,485,991. As
of March 28, 2005 the registrant had outstanding 24,500,648 shares of common
stock.
Portions of the registrant's definitive proxy statement, which will be filed
within 120 days of December 31, 2004, are incorporated by reference into Part
III.
================================================================================
SIGA Technologies, Inc.
Form 10-K
Table of Contents
Page No.
PART I
Item 1. Business..........................................................................2
Item 2. Properties.......................................................................14
Item 3. Legal Proceedings................................................................14
Item 4. Submission of Matters to a Vote of Security Holders..............................14
PART II
Item 5. Market For Registrant's Common Equity, Related Stockholder Matters and
Issuer Purchases of Equity Securities............................................16
Item 6. Selected Financial Data..........................................................17
Item 7. Management's Discussion and Analysis of Financial Condition and Results
of Operations....................................................................18
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.......................33
Item 8. Financial Statements and Supplementary Data......................................34
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial
Disclosure.......................................................................56
Item 9A. Controls and Procedures..........................................................56
Item 9B. Other Information................................................................56
PART III
Item 10. Directors and Executive Officers of the Registrant...............................57
Item 11. Executive Compensation...........................................................57
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related
Stockholder Matters..............................................................57
Item 13. Certain Relationships and Related Transactions...................................57
Item 14. Principal Accountant Fees and Services...........................................57
PART IV
Item 15. Exhibits.........................................................................58
SIGNATURES..................................................................................62
Item 1. Business
Certain statements in this Annual Report on Form 10-K, including certain
statements contained in "Business" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations," constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The
words or phrases "can be," "expects," "may affect," "may depend," "believes,"
"estimate," "project" and similar words and phrases are intended to identify
such forward-looking statements. Such forward-looking statements are subject to
various known and unknown risks and uncertainties and SIGA cautions you that any
forward-looking information provided by or on behalf of SIGA is not a guarantee
of future performance. SIGA's actual results could differ materially from those
anticipated by such forward-looking statements due to a number of factors, some
of which are beyond SIGA's control, including (i) the volatile and competitive
nature of the biotechnology industry, (ii) changes in domestic and foreign
economic and market conditions, and (iii) the effect of federal, state and
foreign regulation on SIGA's businesses. All such forward-looking statements are
current only as of the date on which such statements were made. SIGA does not
undertake any obligation to publicly update any forward-looking statement to
reflect events or circumstances after the date on which any such statement is
made or to reflect the occurrence of unanticipated events.
Introduction
SIGA Technologies, Inc. is referred to throughout this report as "SIGA,"
"the Company," "we" or "us."
SIGA is a biotechnology company incorporated in Delaware on December 9,
1996. We aim to discover, develop and commercialize novel anti-infectives,
antibiotics and vaccines for serious infectious diseases, including products for
use in defense against biological warfare agents such as Smallpox and
Arenaviruses (hemorrhagic fevers). Our anti-viral programs are designed to
prevent or limit the replication of the viral pathogen. Our anti-infectives
programs are aimed at the increasingly serious problem of drug resistance. These
programs are designed to block the ability of bacteria to attach to human
tissue, the first step in the infection process. We are also developing a
technology for the mucosal delivery of our vaccines which may allow the vaccines
to activate the immune system at the mucus lined surfaces of the body -- the
mouth, the nose, the lungs and the gastrointestinal and urogenital tracts -- the
sites of entry for most infectious agents.
Product Candidates and Market Potential
SIGA Biological Warfare Defense Product Portfolio
Anti-Smallpox Drug: While deliberate introduction of any pathogenic agent
would be devastating, we believe the one that holds the greatest potential for
harming the general U.S. population is Smallpox. At present there is no
effective drug with which to treat or prevent Smallpox infections. To address
this serious risk, SIGA scientists have identified a lead drug candidate,
SIGA-246, which inhibits vaccinia, cowpox, ectromelia (mousepox), monkeypox,
camelpox, and variola replication in cell culture but not other unrelated
viruses. Given the safety concerns with the current smallpox vaccine, there
should be several uses for an effective smallpox antiviral drug:
prophylactically, to protect the non-immune who are at risk to exposure;
therapeutically, to prevent disease or death in those exposed to smallpox; and
lastly, as an adjunct treatment to the immunocompromised. SIGA scientists are
also working on several other smallpox drug targets, including the viral
proteinases, to develop additional drug candidates for use in combination
therapy if necessary.
Anti-Arenavirus Drug: Arenaviruses are hemorrhagic fever viruses that have
been classified as Category A agents by the Centers for Disease Control and
Prevention (CDC) due to the great risk that they pose to public health and
national safety. Among the Category A viruses recognized by the Centers for
Disease Control and Prevention, there are four hemorrhagic fever arenaviruses
(Junin, Machupo, Guanarito and Sabia viruses) for which there are no United
States Food and Drug Administration (FDA) approved treatments available. In
order to meet this threat, SIGA scientists have identified a lead drug
candidate, ST-294, which has demonstrated significant antiviral activity in cell
culture assays against arenavirus pathogens. SIGA also has earlier stage
programs against other hemorrhagic fever viruses including Lassa virus,
Lymphocytic choriomeningitis virus (LCMV), and Ebola in development. We
2
believe that the availability of arenavirus antiviral drugs will address
national and global security needs by acting as a significant deterrent and
defense against the use of arenaviruses as weapons of bioterrorism.
Bacterial Commensal Vectors: Our scientists have developed methods that
allow essentially any gene sequence to be expressed in Generally Regarded As
Safe (GRAS) gram-positive bacteria, with the foreign protein being displayed on
the surface of the live recombinant organisms. Since these organisms are
inexpensive to grow and are very stable, this technology affords the possibility
of rapidly producing live recombinant vaccines against any variety of biological
agents that might be encountered, such as Bacillus anthracis (anthrax) or
Smallpox. SIGA scientists are working to develop an alternative vaccine with
improved safety for use in preventing human disease caused by pathogenic
orthopoxviruses such as variola virus. To accomplish this goal we are utilizing
our newly-developed BCV (bacterial commensal vector) technology. BCV utilizes
gram-positive commensal bacteria, such as Streptococcus gordonii, to express
heterologous antigens of interest, either in secreted form or attached to its
external surface. Phase I human clinical trials indicate that this S. gordonii
strain is safe and well-tolerated in humans. In several different animal model
systems S. gordonii has been shown to efficiently express various antigens and
elicit protective immune responses (cellular, humoral and mucosal). We believe
that the delivery of selected vaccinia virus antigens via this live bacterial
vector system will provide an effective and safe method for prevention of
smallpox in humans.
Surface Protein Expression (SPEX) System: Our scientists have harnessed
the protein expression pathways of gram-positive bacteria and turned them into
protein productions factories. Using our proprietary SPEX system, we can produce
foreign proteins at high levels in the laboratory for use in subunit vaccine
formulations. Furthermore, we can envision engineering these bacteria to
colonize the mucosal surfaces of soldiers and/or civilians and secrete
anti-toxins that protect against aerosolized botulism toxin.
Antibiotics: To combat the problems associated with emerging antibiotic
resistance, our scientists are developing drugs designed to hit a new target -
the bacterial adhesion organelles. Specifically, by using novel enzymes required
for the transport and/or assembly of the proteins and structures that bacteria
require for adhesion or colonization, we are developing new classes of broad
spectrum antibiotics. This may prove invaluable in providing prompt treatment to
individuals encountering an unknown bacterial pathogen in the air or food
supply.
Market for Biological Defense Programs.
The U.S. government's proposed budget for the Department of Homeland
Security (the "DHS") for the fiscal year beginning October 1, 2005 includes $2.5
billion of federal spending on Project BioShield. In addition to contributing
funds to the DHS, the Department of Defense will be looking for innovative
approaches to the prevention and treatment of biological warfare agents. One of
the major concerns is Smallpox -- although declared extinct in 1980 by the World
Health Organization, there is a threat that a rogue nation or a terrorist group
may have an illegal inventory of the virus that causes Smallpox. The only legal
inventories of the virus are held under extremely tight security at the Centers
for Disease Control and Prevention (the "Centers for Disease Control") in
Atlanta, Georgia and at a laboratory in Russia. As a result of this threat, the
U.S. government has announced its intent to make significant expenditures on
finding a way to counteract the virus if turned loose by terrorists or on a
battlefield. The Congressional Budget Office (the "CBO") reported that the DHS
projects the acquisition of 60 million doses of new Smallpox vaccines over a
three year period, commencing in 2005. At an estimated $15 per dose, the cost
would be approximately $900 million. Further the CBO reports that the DHS will
spend an additional $1 billion to replace expired stocks in 2007-2013.
The FDA has amended its regulations, effective June 30, 2002, so that
certain new drug and biological products used to reduce or prevent the toxicity
of chemical, biological, radiological, or nuclear substances may be approved for
use in humans based on evidence of effectiveness derived only from appropriate
animal studies and any additional supporting data. We believe that this change
could make it possible for us to have potential products in animal models
approved for sale within a relatively short time frame if our programs are
successful. Our Chief Scientific Officer, Dennis Hruby, has over 20 years
experience working on Smallpox-related research and has been leading a
SIGA/Oregon State University consortium working on an antiviral drug development
project for the past two years.
3
The market potential for our biological warfare defense products has not
been quantified as yet beyond the potential to obtain a share of the
approximately $9 billion the federal government is committing to support
research in the coming year. The government's purchase of approximately $800
million worth of an older version Smallpox vaccines to have an inventory on hand
if needed is evidence of such market potential.
SIGA Anti-Infectives Product Portfolio
Our anti-infectives program is targeted principally toward drug-resistant
bacteria and hospital-acquired infections. According to estimates from the
Centers for Disease Control, approximately two million hospital-acquired
infections occur each year in the United States.
Our anti-infectives approaches aim to block the ability of bacteria to
attach to and colonize human tissue, thereby blocking infection at the first
stage in the infection process. By comparison, antibiotics available today act
by interfering with either the structure or the metabolism of a bacterial cell,
affecting its ability to survive and to reproduce. No currently available
antibiotics target the attachment of a bacterium to its target tissue. We
believe that, by preventing attachment, the bacteria should be readily cleared
by the body's immune system.
Gram-Positive Antibiotic Technology: One of our key anti-infective
programs is based on a novel target for antibiotic therapy. Our scientists have
identified an enzyme, a selective protease, used by most Gram-positive bacteria
to anchor certain proteins to the bacterial cell wall. These surface proteins
are the means by which certain bacteria recognize, adhere to and colonize
specific tissue. Our strategy is to develop protease inhibitors as novel
antibiotics. We believe protease inhibitors will have wide applicability to
Gram-positive bacteria in general, including antibiotic resistant staphylococcus
and a broad range of serious infectious diseases including meningitis and
respiratory tract infections. In 1997, we entered into a collaborative research
and license agreement with Wyeth to identify and develop protease inhibitors as
novel antibiotics. In the first quarter of 2001, we received a milestone payment
from Wyeth for delivery of the first quantities of protease for screening, and
high-throughput screening for protease inhibitors was initiated. In connection
with our effort on this program we have entered into a license agreement with
the University of California at Los Angeles for certain technology that may be
incorporated into our development of products for Wyeth. High throughput
screening of compound libraries has been completed and lead compounds are
currently being evaluated in the laboratory and in animals.
Gram-Negative Antibiotic Technology: In 1998, we entered into a set of
technology transfer and related agreements with MedImmune, Inc., Astra AB and
Washington University, pursuant to which we acquired rights to certain
Gram-negative antibiotic targets, products, screens and services developed at
Washington University. In February 2000, we ended our collaborative research and
development relationship with Washington University on this technology. (See
"Collaborative Research and Licenses"). We maintain a non-exclusive license to
technology acquired through these related agreements. We are using this
technology in the development of antibiotics against Gram-negative pathogens. As
described above, these bacteria use structures called pili to adhere to target
tissue, and we plan to exploit the assembly and export of these essential
infective structures as novel anti-infective targets. We continue to work on
enhancing the intellectual property that we jointly share with Washington
University.
Broad-Spectrum Antibiotic Technology: An initial host response to pathogen
invasion is the release of oxygen radicals, such as superoxide anions and
hydrogen peroxide. The DegP protease is a first-line defense against these toxic
compounds, which are lethal to invading pathogens, and is a demonstrated
virulence factor for several important Gram-negative pathogens: Salmonella
typhimurium, Salmonella typhi, Brucella melitensis and Yersinia enterocolitica.
In all of these pathogens it was demonstrated that organisms lacking a
functional DegP protease were compromised for virulence and showed an increased
sensitivity to oxidative stress. It was also recently demonstrated that in
Pseudomonas aeruginosa conversion to mucoidy, the so-called CF phenotype
involves two DegP homologues.
Our scientists recently demonstrated that the DegP protease is conserved
in Gram-positive pathogens, including S. pyogenes, S. pneumoniae, S. mutans and
S. aureus. Moreover, our investigators have shown a conservation of function of
this important protease in Gram-positive pathogens and we believe that DegP
represents a true broad-spectrum anti-infective development target. Our research
has uncovered a virulence-associated target of the DegP protease that will be
used to design an assay for high-throughput screening for the identification of
lead inhibitors of this potentially important anti-infective target.
4
Market for Anti-infective Programs.
There are currently more than 100 million prescriptions written for
antibiotics annually in the U.S. and we estimate the worldwide market for
antibiotics to be more than $26 billion. Although our products are too early in
development to make accurate assessments of how well they might compete, if
successfully developed and marketed against other products currently existing or
in development at this time, the successful capture of even a relatively small
global market share could lead to a large dollar volume of sales.
Technology
Anti-Infectives Technology: Prevention of Attachment and Infectivity
The bacterial infectious process generally includes three steps:
colonization, invasion and disease. The adherence of bacteria to a host's
surface is crucial to establishing colonization. Bacteria adhere through a
number of mechanisms, but generally by using highly specialized surface
structures which, in turn, bind to specific structures or molecules on the
host's cells or, as discussed below, to inanimate objects residing in the host.
Once adhered, many bacteria will invade the host's cells and either establish
residence or continue invasion into deeper tissues. During any of these stages,
the invading bacteria can cause the outward manifestations of disease, in some
cases through the production and release of toxin molecules. The severity of
disease, while dependent on a large combination of factors, is often the result
of the ability of the bacteria to persist in the host. These bacteria accomplish
this persistence by using surface molecules which can alter the host's
nonspecific mechanisms or its highly specific immune responses to clear or
destroy the organisms.
Unlike conventional antibiotics, our anti-infectives approaches aim to
block the ability of pathogenic bacteria to attach to and colonize human tissue,
thereby preventing infection at its earliest stage. Our scientific strategy is
to inhibit the expression of bacterial surface proteins required for bacterial
infectivity. We believe that this approach has promise in the areas of
hospital-acquired drug-resistant infections and a broad range of other diseases
caused by bacteria.
Many special surface proteins used by bacteria to infect the host are
anchored in the bacterial cell wall. Scientists at The Rockefeller University
("Rockefeller") have identified an amino acid sequence and related enzyme, a
selective protease, that are essential for anchoring proteins to the surface of
most Gram-positive bacteria. Published information indicates that this amino
acid sequence is shared by more than 50 different surface proteins found on a
variety of Gram-positive bacteria. This commonality suggests that this protease
represents a promising target for the development of a new class of antibiotic
products for the treatment of a wide range of infectious diseases. Experiments
by our scientists have shown that without this sequence, proteins cannot become
anchored to the bacterial surface and thus the bacteria are no longer capable of
attachment, colonization or infection. Such "disarmed" bacteria should be
readily cleared by the body's immune system. Our drug discovery strategy is to
use a combination of structure-based drug design and high throughput screening
procedures to identify compounds that inhibit the protease, thereby blocking the
anchoring process. If successful, this strategy should provide relief from many
Gram-positive bacterial infections, but may prove particularly important in
combating diseases caused by the emerging antibiotic resistance of the
Gram-positive organisms Streptococcu, aureus, Streptococcus pneumoniae, and the
enterococci.
In contrast to the above program, which focuses on Gram-positive bacteria,
our pilicide program, based upon initial research performed at Washington
University in St. Louis ("Washington University"), focuses on a number of new
and novel targets all of which impact on the ability of Gram-negative bacteria
to assemble adhesive pili on their surfaces. Pili are proteins on the surfaces
of Gram-negative bacteria -- such as E. coli, salmonella, and shigella -- that
are required for the attachment of the bacteria to human tissue, the first step
in the infection process. This research program is based upon the
well-characterized interaction between a periplasmic protein -- a chaperone --
and the protein subunits required to form pili. In addition to describing the
process by which chaperones and pili subunits interact, we have developed an
assay systems necessary to screen for potential therapeutic compounds, and have
provided an initial basis for selecting novel antibiotics that work by
interfering with the pili adhesion mechanism.
5
Vaccine Technologies: Mucosal Immunity and Vaccine Delivery
Using proprietary technology licensed from Rockefeller, SIGA is developing
specific commensal bacteria ("commensals") as a means to deliver mucosal
vaccines. Commensals are harmless bacteria that naturally occupy the body's
surfaces with different commensals inhabiting different surfaces, particularly
the mucosal surfaces. Our vaccine candidates use genetically engineered
commensals to deliver antigens for a variety of pathogens to the mucosal immune
system. When administered, the genetically engineered commensals colonize the
mucosal surface and replicate. By activating a local mucosal immune response,
our vaccine candidates are designed to prevent infection and disease at the
earliest possible stage, as opposed to most conventional vaccines which are
designed to act after infection has already occurred.
Our commensal vaccine candidates use Gram-positive bacteria. Rockefeller
scientists have identified a protein region that is used by Gram-positive
bacteria to anchor proteins to their surfaces. We are using the proprietary
technology licensed from Rockefeller to combine antigens from a wide range of
infectious organisms, both viral and bacterial, with the surface protein anchor
region of a variety of commensal organisms. By combining a specific antigen with
a specific commensal, vaccines may be tailored to both the target pathogen and
its mucosal point of entry.
To target an immune response to a particular mucosal surface, a commensal
vaccine would employ a commensal organism that naturally inhabits that surface.
For example, vaccines targeting sexually transmitted diseases might employ
Lactobacillus acidophilus, a commensal colonizing the female urogenital tract.
Vaccines targeting gastrointestinal diseases could employ Lactobacillus casei, a
commensal colonizing the gastrointestinal tract. We have conducted initial
experiments using Streptococcus gordonii ("S. gordonii"), a commensal that
colonizes the oral cavity and which may be used in vaccines targeting pathogens
that enter through the upper respiratory tract, such as the influenza virus.
By using an antigen unique to a given pathogen, the technology may
potentially be applied to any infectious agent that enters the body through a
mucosal surface. Our scientists have expressed and anchored a variety of viral
and bacterial antigens on the outside of S. gordonii, including the M6 protein
from group A streptococcus, a group of organisms that causes a range of
diseases, including strep throat, necrotizing fasciitis, impetigo and scarlet
fever. In addition, proteins from other infectious agents, such as HIV and human
papilloma virus have also been expressed using this system. We believe this
technology will enable the expression of most antigens regardless of size or
shape. In animal studies, we have shown that the administration of a genetically
engineered S. gordonii vaccine prototype induces both a local mucosal immune
response and a systemic immune response.
We believe that mucosal vaccines developed using our proprietary commensal
delivery technology could provide a number of advantages, including:
o More complete protection than conventional vaccines: Mucosal
vaccines in general may be more effective than conventional
parenteral vaccines, due to mucosal vaccines' ability to produce
both a systemic and local (mucosal) immune response.
o Safety advantage over other live vectors: A number of bacterial
pathogens have been genetically rendered less infectious, or
attenuated, for use as live vaccine vectors. Commensals, by virtue
of their substantially harmless nature, may offer a safer delivery
vehicle without fear of genetic reversion to the infectious state
inherent in attenuated pathogens.
o Non-injection administration: Oral, nasal, rectal or vaginal
administration of the vaccine eliminates the need for painful
injections with their potential adverse reactions.
o Potential for combined vaccine delivery: The Children's Vaccine
Initiative, a worldwide effort to improve vaccination of children
sponsored by the World Health Organization (WHO), has called for the
development of combined vaccines, specifically to reduce the number
of needle sticks per child, by combining several vaccines into one
injection, thereby increasing compliance and decreasing disease. We
believe our commensal delivery technology can be an effective method
of delivery of multi-component
6
vaccines within a single commensal organism that address multiple
diseases or diseases caused by multiple strains of an infectious
agent.
o Eliminating need for refrigeration: One of the problems confronting
the effective delivery of parenteral vaccines is the need for
refrigeration at all stages prior to injection. The stability of the
commensal organisms in a freeze-dried state would, for the most
part, eliminate the need for special climate conditions, a critical
consideration, especially for the delivery of vaccines in developing
countries.
o Low cost production: By using a live bacterial vector, extensive
downstream processing is eliminated, leading to considerable cost
savings in the production of the vaccine. The potential for
eliminating the need for refrigeration would add considerably to
these savings by reducing the costs inherent in refrigeration for
vaccine delivery.
Strep Throat Vaccine Candidate. Until the age of 15, many children suffer
from recurrent strep throat infections. Up to three percent of ineffectively
treated strep throat cases progress to rheumatic fever, a debilitating heart
disease, which worsens with each succeeding streptococcal infection. Since the
advent of penicillin therapy, rheumatic fever in the United States has
experienced a dramatic decline. However, in the last two decades, rheumatic
fever has experienced a resurgence in the United States. Part of the reason for
this is the latent presence of this organism in children who do not display
symptoms of a sore throat, and, therefore, remain untreated and at risk for
development of rheumatic fever. Based on data from the Centers for Disease
Control and Prevention, there are five to 10 million cases of pharyngitis due to
group A streptococcus in the United States each year. There are over 32 million
children in the principal age group targeted by us for vaccination. Worldwide,
it is estimated that one percent of all school age children in the developing
world have rheumatic heart disease. Additionally, despite the relative ease of
treating strep throat with antibiotics, the specter of antibiotic resistance is
always present. In fact, resistance to erythromycin, the second line antibiotic
in patients allergic to penicillin, has appeared in a number of cases.
o We believe that the reason no vaccine for strep throat has been
developed is because of problems associated with identifying an
antigen that is common to the more than 120 different serotypes of
group A streptococcus, the bacterium that causes the disease. We
have licensed from Rockefeller a proprietary antigen which is common
to most types of group A streptococcus, including types that have
been associated with rheumatic fever. When this antigen was orally
administered to animals, it was shown to provide protection against
multiple types of group A streptococcal infection. Using this
antigen, we are seeking to develop a mucosal vaccine for strep
throat.
o SIGA has taken a parallel vaccine development track with two
formulations of the cross-protective streptococcal antigen. One
approach expresses the strep throat antigen on the surface of the
commensal bacterium, Streptococcus gordonii, which lives on the
surface of the teeth and gums. Pre-clinical research in mice and
rabbits has established the ability of this vaccine candidate to
colonize and induce both a local and systemic immune response. The
other candidate uses a subunit (purified protein) approach, in which
the antigen is delivered intranasally with a mucosal adjuvant
(enhances the immune response). Like the commensal approach, the
subunit approach has provided significant protection in mice from
challenges by multiple serotypes. We are collaborating with the
National Institutes of Health ("NIH") and the University of Maryland
Center for Vaccine Development on the clinical development of this
vaccine candidate. In cooperation with the NIH we filed an
Investigational New Drug Application ("IND") with the FDA in
December 1997. The first stage of these clinical trials, using the
commensal delivery system without the strep throat antigen, were
completed at the University of Maryland in 2000. The study showed
the commensal delivery system to be well-tolerated and that it
spontaneously eradicated or was easily eradicated by conventional
antibiotics. A second clinical trial of the commensal delivery
system without the strep throat antigen was initiated in 2000 at the
University of Maryland. The study was completed in January 2002 and
the results corroborated the results of the earlier study regarding
tolerance and spontaneous eradication. Further development continues
principally on the subunit approach, which is currently in
pre-clinical studies.
o In the U.S. there are about 19 million children aged 2 to 6 years
who could be candidates to receive such a vaccine at the time of its
introduction and then around 4 million babies born each year to be
protected. Assuming a charge of $25 per dose and three doses needed
for protection, there could be a potential market
7
for a strep throat vaccine of $1.4 billion to immunize the entire
U.S. population of 2 to 6 year olds and, thereafter, $300 million
per year to maintain immunization in new births.
Surface Protein Expression System ("SPEX")
The ability to overproduce many bacterial and human proteins has been made
possible through the use of recombinant DNA technology. The introduction of DNA
molecules into E. coli has been the method of choice to express a variety of
gene products, because of these bacteria's rapid reproduction and
well-understood genetics. Yet despite the development of many efficient E.
coli-based gene expression systems, the most important concern continues to be
associated with subsequent purification of the product. Recombinant proteins
produced in this manner do not readily cross E. coli's outer membrane, and as a
result, proteins must be purified from the bacterial cytoplasm or periplasmic
space. Purification of proteins from these cellular compartments can be very
difficult. Frequently encountered problems include low product yields,
contamination with potentially toxic cellular material (i.e., endotoxin) and the
formation of large amounts of partially folded polypeptide chains in non-active
aggregates termed inclusion bodies.
To overcome these problems, we have taken advantage of our knowledge of
Gram-positive bacterial protein expression and anchoring pathways. This pathway
has evolved to handle the transport of surface proteins that vary widely in
size, structure and function. Modifying the approach used to create commensal
mucosal vaccines, we have developed methods which, instead of anchoring the
foreign protein to the surface of the recombinant Gram-positive bacteria, result
in it being secreted into the surrounding medium in a manner which is readily
amenable to simple batch purification. We believe the advantages of this
approach include the ease and lower cost of Gram-positive bacterial growth, the
likelihood that secreted recombinant proteins will be folded properly, and the
ability to purify recombinant proteins from the culture medium without having to
disrupt the bacterial cells and liberating cellular contaminants. Gram-positive
bacteria may be grown simply in scales from those required for laboratory
research up to commercial mass production.
Collaborative Research and Licenses
We have entered into the following license agreements and collaborative
research arrangements:
Rockefeller University. In accordance with an exclusive worldwide license
agreement with Rockefeller, we have obtained the right and license to make, use
and sell mucosal vaccines based on gram-positive organisms and products for the
therapy, prevention and diagnosis of diseases caused by streptococcus,
staphylococcus and other organisms. The license covers eight issued U.S. patents
and three issued European patents, as well as one pending U.S. patent
application and one pending European application. The issued United States
patents expire in 2008, 2014 (4), 2015 (2), and 2016. respectively. The
agreement generally requires us to pay royalties on sales of products developed
from the licensed technologies, and fees on revenues from sublicensees, where
applicable, and we are responsible for the costs of filing and prosecuting
patent applications. The agreement also requires us to pay 15% of certain
milestone payments we receive from Wyeth to Rockefeller, if any, under our
collaborative and license agreement with Wyeth. Accordingly, under the
agreement, which is our only agreement that requires us to make milestone
payments, we could be required to make milestone payments to Rockefeller of up
to an aggregate amount of approximately $1.1 million. To date, we have not
received any milestone payments from Wyeth that would require us to make a
payment to Rockefeller. The primary potential products from this collaboration
are the strep vaccine and the broad spectrum antibiotic. Under the agreement, we
paid the university approximately $850,000 to support research at Rockefeller.
The agreement to fund research has ended and no payments have been made to the
university since the year ended December 31, 1999. Under the agreement we are
obligated to pay Rockefeller a royalty on net sales by SIGA at rates between
2.5% and 5% depending on product and amount of sales. On sales by any
sub-licensee, we will pay Rockefeller a royalty of 15% of anything we receive.
The term of the agreement is for the duration of the patents licensed. As we do
not currently know when any patents pending or future patents will expire, we
cannot at this time determine the term of this agreement. At the end of that
term of the agreement, we have the right to continue to practice the then
existing technical information as a fully paid, perpetual license. The agreement
can be terminated earlier if we are in breach of the provisions of the agreement
and do not cure the breach in the allowed cure period. We are compliant in all
our obligations under the agreement.
8
Oregon State University. Oregon State University ("OSU") is also a party
to our license agreement with Rockefeller, whereby we have obtained the right
and license to make, use and sell products for the therapy, prevention and
diagnosis of diseases caused by streptococcus. Pursuant to a separate research
support agreement with OSU, we provided funding for sponsored research through
December 31, 1999, with exclusive license rights to all inventions and
discoveries resulting from this research. At this time, no additional funding is
contemplated under this agreement, however, we retain the exclusive licensing
rights to the inventions and discoveries that may arise from this collaboration.
The term of the agreement is for the duration of the patents licensed. As we do
not currently know when any patents pending or future patents will expire, we
cannot at this time determine the term of this agreement. The agreement can be
terminated earlier if we are in breach of the provisions of the agreement and do
not cure the breach in the allowed cure period. We are compliant in all our
obligations under the agreement.
During 1999, we acquired an option to enter into a license with OSU in
which we will acquire the rights to certain technology pertaining to the
potential development of a chlamydia vaccine. In February 2000, we exercised our
option and pursuant to an exclusive license agreement dated March 2000, we have
made payments to OSU of approximately $25,000 as part of our obligation under
the option.
In September 2000, we entered into a subcontract with OSU. The contract is
for a project which is targeted towards developing novel antiviral drugs capable
of preventing disease and pathology for Smallpox in the event this pathogen were
to be used as an agent of bioterrorism. The project is being funded by a grant
from the NIH. The basic virology aspects of the project will be conducted at OSU
and the drug development will be performed by us under the subcontract. The
budget for the subcontract work was negotiated on a year by year basis with OSU
and depended on the progress of the program and funding available. In the year
ended December 31, 2001 we recognized revenue of $15,000. On October 5, 2001 the
agreement was extended through August 31, 2002. For the period ended December
31, 2002 we recognized $75,000 in revenue. The agreement was extended again
through August 31, 2003. The sub-contract is on a year to year renewal. Through
December 31, 2003 we received a total of $130,000 under the agreement. During
the year ended December 31, 2003 work under the subcontract was completed.
Wyeth. We have entered into a collaborative research and license agreement
with Wyeth in connection with the discovery and development of anti-infectives
for the treatment of gram-positive bacterial infections. Pursuant to the
agreement, Wyeth provided funding for a joint research and development program,
subject to certain milestones, through September 30, 1999 and is responsible for
additional milestone payments. In May 2001, we entered into an amendment to the
July 1, 1997 agreement. The amendment extended the term of the original
agreement to September 30, 2001. The extension provided for Wyeth to continue to
pay us at a rate of $450,000 per year through the term of the amended agreement.
During the term of the agreement as amended, we received $787,500 from Wyeth to
support work performed by SIGA under the agreement and $237,500 for achieving a
research milestone. For the year ended December 31, 2001 we recognized revenue
of $1,025,000. The agreement to fund additional research was not extended beyond
September 30, 2001.
Wyeth is obligated to make milestone payments to us as any product
developed progresses through the FDA approval process under our agreement with
Wyeth, which is the only agreement pursuant to which we are entitled to receive
milestone payments. For products developed we could receive up to approximately
$13 million in milestone payments for approval of the product in the U.S. and
Japan. We would also receive royalty payments of 2% on the first $300,000 of
cumulative licensed product sales, 4% on annual sales up to $100 million, 6% on
annual sales between $100 million and $250 million and 8% on annual sales above
$250 million. The license will expire on the earlier of 10 years or the last to
expire issued patent. Wyeth has the right to terminate the agreement early, on
ninety days written notice. If terminated early, all rights granted to Wyeth
revert to SIGA except with respect to any compound identified by Wyeth as of the
date of termination and subject to the milestone and royalty obligations of the
agreement.
National Institutes of Health. We have entered into a clinical trials
agreement with the NIH pursuant to which the NIH, with our cooperation, will
conduct clinical trials of our strep throat vaccine candidate. The agreement
will fund trials through Phase II of the FDA approval process. To date, two
Phase I clinical trials have been conducted for the strep vaccine delivery
system. We are working to optimize and test the vaccine formulation prior to
initiating Phase I clinical trials with the recombinant commensal vector based
vaccine. The agreement may
9
be terminated unilaterally by the parties upon sixty days prior notice. If
terminated we will receive copies of all data, reports and other information
related to the trials and any unused vaccine.
Prior to 2002 we received grants amounting to $247,000 to support our
antibiotic and vaccine development programs. In June 2002, we received a Phase
II Small Business Innovation Research (SBIR) grant for approximately $865,000.
The grant was for the two year period beginning June, 1, 2002 and ending May 31,
2004. In August 2004 we were awarded two Phase I and two Phase II grants
totaling approximately $12.1 million to support our work on Smallpox and
Arenaviruses. The grants were acquired as part of our acquisition of certain
assets from ViroPharma Incorporated ("Viropharma"). For the years ending
December 31, 2004, 2003 and, 2002, we have recognized revenue from the SBIR
grants of $1,415,000, $388,000 and $270,000, respectively.
As part of our operational strategy we routinely submit grants to the NIH.
There is no assurance that we will receive additional grants.
Washington University. In February 1998, we entered into a research
collaboration and worldwide license agreement with Washington University
pursuant to which we obtained the right and license to make, use and sell
antibiotic products based on gram-negative technology for all human and
veterinary diagnostic and therapeutic uses. The license covered five pending
United States patent applications and corresponding foreign patent applications.
The agreement generally required us to pay royalties on sales of products
developed from the licensed technologies and fees on revenues from sublicensees,
where applicable, and we were responsible for certain milestone payments and for
the costs of filing and prosecuting patent applications. Pursuant to the
agreement, we agreed to provide funding to Washington University for sponsored
research through February 6, 2001, with exclusive license rights to all
inventions and discoveries resulting from this research. During 1999, a dispute
arose between the parties regarding their respective performance under the
agreement. In February 2000, the parties reached a settlement agreement and
mutual release of their obligations under the research collaboration agreement.
Under the terms of the settlement, we are released from any further payments to
Washington University and have disclaimed any rights to the patents licensed
under the original agreement. As part of the settlement agreement, we entered
into a non-exclusive license to certain patents covered in the original
agreement. SIGA and Washington University will share equally the responsibility
for the administration and the expenses for the prosecution of patent
applications and /or patents in the agreement. The collaboration is for the
gram-negative product opportunity. We will receive licensing revenue from
Washington University that derives from the commercialization of products
covered by patent rights of the agreement. The royalty will be 20% of the first
$400,000 received and 10% of the next $1,000,000 received with a total payment
of licensing revenues to us not to exceed $500,000. The term of our agreement
with Washington University is for the duration of the patents and a number of
pending patents. As we do not currently know when any patents pending or future
patents will expire, we cannot at this time definitively determine the term of
this agreement. The agreement cannot be terminated unless we fail to pay our
share of the joint patent costs for the technology licensed. We have currently
met all our obligations under this agreement.
Abbott Laboratories. In March 2000, we entered into an agreement with the
Ross Products Division of Abbott Laboratories ("Ross"). The agreement grants
Ross an exclusive option to negotiate an exclusive license to certain SIGA
technology and patents in addition to certain research development services. In
exchange for research services and the option, Ross was obligated to pay us
$120,000 in three installments of $40,000. The first payment of $40,000 was
received in March 2000 and was recognized ratably, over the term of the
arrangement. The remaining installments are contingent upon meeting certain
milestones under the agreement and will be recognized as revenue upon completion
and acceptance of such milestones. The first milestone was met, and we received
an additional payment of $40,000 in the quarter ended September 30, 2000. During
the years ended December 31, 2001 and 2000, we recognized revenue in the amount
of $45,000 and $80,000, respectively. The development agreement was for a
sexually transmitted disease potential product opportunity. The research program
was completed in late 2001 and additional work was performed into 2003, however
the additional work could not be completed due to the inability of one of our
sub-contractors to perform. As a result, we gave Ross notice of termination on
January 26, 2004 and all rights to the technology reverted to us.
Regents of the University of California. In December 2000, we entered into
an exclusive license agreement and a sponsored research agreement with the
Regents of the University of California ("Regents"). Under the license agreement
we obtained rights for the exclusive commercial development, use and sale of
products related to certain inventions in exchange for a non-refundable license
issuance fee of $15,000 and an annual maintenance
10
fee of $10,000. As of December 31, 2004 we have made payments of approximately
$91,000 under the license. In the event that we sub-license the license, we must
pay Regents 15% of all royalty payments made to SIGA. Under the agreement, we
will also pay Regents 15% of all royalties received from Wyeth. The agreement
applies to the gram positive product opportunity and our collaborative agreement
with Wyeth. The term of the agreement is until the expiration of the
last-to-expire patent licensed under this agreement. The agreement may be
terminated by Regents if we default on any of our obligations, the agreement
with Wyeth is terminated and a substitute agreement is not entered into or if we
give notice that we do not intend to make product from the licensed technology.
We have currently met all our obligations under this agreement.
U.S. Army Medical Research Acquisition Activity. In December 2002, we
entered into a four years contract with the U.S. Army Medical Research
Acquisition Activity (USAMRAA) to develop a drug to treat Smallpox. The contract
start date was January 1, 2003 and the total amount approximated $1.6 million.
Annual payments over the term of the agreement will be approximately $400,000.
TransTech Pharma, Inc. In October 2002, we entered into a drug discovery
collaboration agreement with TransTech Pharma, Inc. ("TransTech Pharma"). Under
the agreement, SIGA and TransTech Pharma collaborate on the discovery,
optimization and development of lead compounds to therapeutic agents. The costs
of development are shared. SIGA and TransTech Pharma would share revenues
generated from licensing and profits from any commercialized product sales. The
agreement will be in effect until terminated by the parties or upon cessation of
research or sales of all products developed under the agreement. If the
agreement is terminated, relinquished or expires for any reason certain rights
and benefits will survive the termination. Obligations not expressly indicated
to survive the agreement will terminate with the agreement. No revenues were
recognized in 2004, 2003 and 2002 from this collaboration.
Intellectual Property and Proprietary Rights
Our commercial success will depend in part on our and our collaborators'
ability to obtain and maintain patent protection for our proprietary
technologies, drug targets and potential products and to effectively preserve
our trade secrets. Because of the substantial length of time and expense
associated with bringing potential products through the development and
regulatory clearance processes to reach the marketplace, the pharmaceutical
industry places considerable importance on obtaining patent and trade secret
protection. The patent positions of pharmaceutical and biotechnology companies
can be highly uncertain and involve complex legal and factual questions. No
consistent policy regarding the breadth of claims allowed in biotechnology
patents has emerged to date. Accordingly, we cannot predict the type and breadth
of claims allowed in these patents.
We have licensed the rights to eight issued U.S. patents and three issued
European patents. These patents have varying lives and they are related to the
technology licensed from Rockefeller University for the Strep and Gram-positive
products. We have one additional patent application in the U.S. and one
application in Europe relating to this technology. We are joint owner with
Washington University of seven issued patents in the U.S. and one in Europe. In
addition, there are four co-owned U.S. patent applications. These patents are
for the technology used for the gram-negative product opportunities. We are also
exclusive owner of one U.S. patent and three U.S. patent applications. One of
these U.S. patent applications relates to our DegP product opportunities.
The following are our patent positions as of December 31, 2004.
- ----------------------------------------------------------------------------------------------------------------------
Number
Number Number Exclusively Number
Exclusively Co-Exclusively Licensed Exclusively Number
PATENTS Licensed Licensed from Licensed Owned by Patent Expiration Dates
from with Oregon from UCLA SIGA
Rockefeller Washington State
Univ. Univ. University
- ----------------------------------------------------------------------------------------------------------------------
2008, 2013(2), 2014 (6),
U.S. 8 7 1 1 2015 (2), 2016 (2), 2017,
2019, 2020 (2)
- ----------------------------------------------------------------------------------------------------------------------
11
- ----------------------------------------------------------------------------------------------------------------------
Number
Number Number Exclusively Number
Exclusively Co-Exclusively Licensed Exclusively Number
PATENTS Licensed Licensed from Licensed Owned by Patent Expiration Dates
from with Oregon from UCLA SIGA
Rockefeller Washington State
Univ. Univ. University
- ----------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------
2009, 2013, 2014 (2),
Australia 5 2 1 2015, 2016, 2019,2020
- ----------------------------------------------------------------------------------------------------------------------
Canada 2 2010, 2019
- ----------------------------------------------------------------------------------------------------------------------
Europe 3 1 1 2009, 2010, 2013, 2019,
2020
- ----------------------------------------------------------------------------------------------------------------------
Hungary 1 2013
- ----------------------------------------------------------------------------------------------------------------------
Japan 2 2010, 2012
- ----------------------------------------------------------------------------------------------------------------------
Mexico 1 2016
- ----------------------------------------------------------------------------------------------------------------------
New Zealand 1 2016
- ----------------------------------------------------------------------------------------------------------------------
China 1 2016
- ----------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------
Number
Number Number Exclusively
Exclusively Co-Exclusively Licensed Number Number
Licensed Licensed from Exclusively Owned by
APPLICATIONS from with Oregon Licensed SIGA
Rockefeller Washington State from UCLA
Univ. Univ. University
- -----------------------------------------------------------------------------------------------
U.S. applications 1 4 2 3
- -----------------------------------------------------------------------------------------------
U.S. provisionals 4
- -----------------------------------------------------------------------------------------------
PCT 2
- -----------------------------------------------------------------------------------------------
Australia 1 1 2
- -----------------------------------------------------------------------------------------------
Canada 3 2 2 1 1
- -----------------------------------------------------------------------------------------------
Europe 1 1 1 1 2
- -----------------------------------------------------------------------------------------------
Finland 1
- -----------------------------------------------------------------------------------------------
Japan 3 2 1 1 2
- -----------------------------------------------------------------------------------------------
Hungary 1
- -----------------------------------------------------------------------------------------------
We also rely upon trade secret protection for our confidential and
proprietary information. No assurance can be given that other companies will not
independently develop substantially equivalent proprietary information and
techniques or otherwise gain access to our trade secrets or that we can
meaningfully protect our trade secrets.
Government Regulation
Regulation by governmental authorities in the United States and other
countries will be a significant factor in the production and marketing of any
biopharmaceutical products that we may develop. The nature and the extent to
which such regulations may apply to us will vary depending on the nature of any
such products. Virtually all of our potential biopharmaceutical products will
require regulatory approval by governmental agencies prior to commercialization.
In particular, human therapeutic products are subject to rigorous pre-clinical
and clinical testing and other approval procedures by the FDA and similar health
authorities in foreign countries. Various federal statutes and regulations also
govern or influence the manufacturing, safety, labeling, storage, record keeping
and marketing of such products. The process of obtaining these approvals and the
subsequent compliance with appropriate federal and foreign statutes and
regulations requires the expenditure of substantial resources.
12
In order to test clinically, produce and market products for diagnostic or
therapeutic use, a company must comply with mandatory procedures and safety
standards established by the FDA and comparable agencies in foreign countries.
Before beginning human clinical testing of a potential new drug, a company must
file an IND and receive clearance from the FDA. This application is a summary of
the pre-clinical studies that were conducted to characterize the drug, including
toxicity and safety studies, as well as an in-depth discussion of the human
clinical studies that are being proposed.
The pre-marketing program required for approval by the FDA of a new drug
typically involves a time-consuming and costly three-phase process. In Phase I,
trials are conducted with a small number of patients to determine the early
safety profile, the pattern of drug distribution and metabolism. In Phase II,
trials are conducted with small groups of patients afflicted with a target
disease in order to determine preliminary efficacy, optimal dosages and expanded
evidence of safety. In Phase III, large scale, multi-center comparative trials
are conducted with patients afflicted with a target disease in order to provide
enough data for statistical proof of efficacy and safety required by the FDA and
others.
The FDA has amended its regulations, effective June 30, 2002, so that
certain new drug and biological products used to reduce or prevent the toxicity
of chemical, biological, radiological, or nuclear substances may be approved for
use in humans based on evidence of effectiveness derived only from appropriate
animal studies and any additional supporting data. To date, the FDA has not
given clearance to any products submitted under the amended regulations.
The FDA closely monitors the progress of each of the three phases of
clinical testing and may, in its discretion, reevaluate, alter, suspend or
terminate the testing based on the data that have been accumulated to that point
and its assessment of the risk/benefit ratio to the patient. Estimates of the
total time required for carrying out such clinical testing vary between two and
ten years. Upon completion of such clinical testing, a company typically submits
a New Drug Application ("NDA") or Product License Application ("PLA") to the FDA
that summarizes the results and observations of the drug during the clinical
testing. Based on its review of the NDA or PLA, the FDA will decide whether to
approve the drug. This review process can be quite lengthy, and approval for the
production and marketing of a new pharmaceutical product can require a number of
years and substantial funding; there can be no assurance that any approvals will
be granted on a timely basis, if at all.
Once the product is approved for sale, FDA regulations govern the
production process and marketing activities, and a post-marketing testing and
surveillance program may be required to monitor continuously a product's usage
and its effects. Product approvals may be withdrawn if compliance with
regulatory standards is not maintained. Other countries in which any products
developed by us may be marketed could impose a similar regulatory process.
Commercialization of animal health products can be accomplished more
rapidly than human health products. Unlike the human market, potential vaccine
or therapeutic products can be tested directly on the target animal as soon as
the product leaves the research laboratory. The data collected in these trials
is submitted to the U.S. Department of Agriculture for review and eventual
product approval.
Competition
The biotechnology and pharmaceutical industries are characterized by
rapidly evolving technology and intense competition. Our competitors include
most of the major pharmaceutical companies, which have financial, technical and
marketing resources significantly greater than ours. Biotechnology and other
pharmaceutical competitors include Acambis, AVI Biopharma, Avant
Immuno-therapeutics, Inc, Bavarian Nordic AS, Chimerix Inc., Dynport Vaccine
Company, Bioport, Dor Biopharma, Inc., Pharmathene, and Microbiotix, Inc.
Academic institutions, governmental agencies and other public and private
research organizations are also conducting research activities and seeking
patent protection and may commercialize products on their own or through joint
venture. There can be no assurance that our competitors will not succeed in
developing products that are more effective or less costly than any which are
being developed by us or which would render our technology and future products
obsolete and noncompetitive.
13
Human Resources and Facilities
As of March 14, 2005 we had 35 full time employees. None of our employees
are covered by a collective bargaining agreement and we consider our employee
relations to be good.
Availability of Reports and Other Information
We file annual, quarterly, and current reports, proxy statements, and
other documents with the Securities and Exchange Commission ("SEC") under the
Securities Exchange Act of 1934 (the "Exchange Act"). The public may read and
copy any materials that we file with the SEC at the SEC's Public Reference Room
at 450 Fifth Street, NW, Washington, DC 20549. The public may obtain information
on the operation of the Public Reference Room by calling the SEC at
1-800-SEC-0330. Also, the SEC maintains an Internet website that contains
reports, proxy and information statements, and other information regarding
issuers, including us, that file electronically with the SEC. The public can
obtain any documents that we file with the SEC at http://www.sec.gov.
In addition, our company website can be found on the Internet at
www.siga.com. The website contains information about us and our operations.
Copies of each of our filings with the SEC on Form 10-K, Form 10-KSB, Form 10-Q,
Form 10-QSB and Form 8-K, and all amendments to those reports, can be viewed and
downloaded free of charge as soon as reasonably practicable after the reports
and amendments are electronically filed with or furnished to the SEC. To view
the reports, access www.siga.com/investor.html and click on "SEC Filing".
The following corporate governance related documents are also available on
our website:
o Code of Ethics and Business Conduct
o Amended and Restated Audit Committee Charter
o Compensation Committee Charter
o Nominating and Corporate Governance Committee Charter
o Procedure for Sending Communications to the Board of Directors
o Procedures for Security Holder Submission of Nominating
Recommendations
o 2004 Policy on Confidentiality of Information and Securities Trading
To review these documents, access www.siga.com/investor.html and click on
"Corporate Governance". Any of the above documents can also be obtained in print
by any shareholder upon request to the Secretary, SIGA Technologies, Inc., 420
Lexington Avenue, Suite 408, New York, New York 10170
Item 2. Properties
Our headquarters are located in New York City and our research and
development facilities are located in Corvallis, Oregon. In New York, we lease
approximately 3,000 square feet under a lease that expires in November 2007. In
Corvallis, we lease approximately 10,000 square feet under a lease that expires
in December 2007.
Item 3. Legal Proceedings
SIGA is not a party, nor is its property the subject of, any pending legal
proceedings other than routine litigation incidental to its business.
Item 4. Submission of Matters to a Vote of Security Holders
At our Annual Meeting of Stockholders held on December 14, 2004, our
stockholders elected our Board of Directors and ratified our selection of
independent registered public accounting firm:
14
The following nominees were elected to our Board of Directors upon the
following votes:
Director Votes For Withheld
-------- --------- --------
Donald G. Drapkin 20,719,841 914,668
Bernard L. Kasten, M.D. 21,456,084 178,425
Thomas E. Constance 21,454,002 180,507
Adnan M. Mjalli, Ph.D. 21,457,759 176,750
Mehmet C. Oz, M.D. 20,717,866 916,643
Eric A. Rose, M.D. 21,458,009 175,500
Paul G. Savas 21,457,602 176,907
Michael A. Weiner, M.D. 21,459,189 175,320
Judy S. Slotkin 21,459,682 174,827
James J. Antal 21,457,264 177,245
Our stockholders ratified the selection of PricewaterhouseCoopers LLP as
our independent registered public accounting firm for the fiscal year ending
December 31, 2004 by casting 21,550,273 votes in favor of this proposal, 26,320
votes against the proposal and 57,916 abstained.
15
PART II
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and
Issuer Purchases of Equity Securities
Price Range of Common Stock
Our common stock has been traded on the Nasdaq SmallCap Market since
September 9, 1997 and trades under the symbol "SIGA." Prior to that time there
was no public market for our common stock. The following table sets forth, for
the periods indicated, the high and low closing sales prices for the common
stock, as reported on the Nasdaq SmallCap Market.
Price Range
2003 High Low
First Quarter ..................................... $ 1.49 $ 1.02
Second Quarter .................................... $ 1.91 $ 1.09
Third Quarter ..................................... $ 2.13 $ 1.61
Fourth Quarter .................................... $ 2.60 $ 1.80
2004 High Low
First Quarter ..................................... $ 2.34 $ 1.85
Second Quarter .................................... $ 1.93 $ 1.29
Third Quarter ..................................... $ 1.63 $ 1.23
Fourth Quarter .................................... $ 1.75 $ 1.35
As of March 28, 2005, the closing bid price of our common stock was $1.53
per share. There were 106 holders of record as of March 28, 2005. We believe
that the number of beneficial owners of our common stock is substantially
greater than the number of record holders, because a large portion of common
stock is held in broker "street names."
We have paid no dividends on our common stock and we do not expect to pay
cash dividends in the foreseeable future. We are not under any contractual
restriction as to our present or future ability to pay dividends. We currently
intend to retain any future earnings to finance the growth and development of
our business.
Recent Sales of Unregistered Securities
All of the following sales of unregistered securities were made without
registration under the Securities Act in reliance upon the exemption from
registration afforded under Section 4(6) of the Securities Act and Rule 506 of
Regulation D promulgated thereunder. Accordingly, the transfer of the securities
is subject to substantial restrictions. Securities were only purchased by
"Accredited Investors" as that term is defined under Rule 501 of Regulation D.
Proceeds from the offerings were used for general working capital purposes.
In August 2004, we acquired certain government grants and two early stage
antiviral programs, Smallpox and Arenavirus, targeting certain agents of
biological warfare from ViroPharma. As part of the purchase price for these
assets they were issued 1,000,000 shares of our common stock.
In August 2003, we entered into an agreement with MacAndrews & Forbes
Holdings Inc. ("MacAndrews & Forbes"), a holding company of which the Company's
Chairman of the Board of Directors is Vice Chairman and a director. Upon
consummation of the agreement, MacAndrews & Forbes and its permitted assignees
invested an initial $1,000,000 in SIGA in exchange for 694,444 shares of our
common stock at a price of $1.44 per share and warrants to purchase 347,222
shares of common stock at an initial exercise price of $2.00 per share.
MacAndrews & Forbes and its permitted assignees also received an option,
exercisable through October 13, 2003, to invest up to an additional $9,000,000
in SIGA on the same terms. Upon exercise of the option in October 2003, we
received gross
16
proceeds of $2,159,405 in exchange for 1,499,587 shares of common stock at a
price of $1.44 per share and warrants to purchase 749,794 shares of common stock
at an initial exercise price of $2.00 per share. In January 2004, upon approval
of the Company's shareholders, MacAndrews & Forbes and its permitted assignee,
TransTech Pharma, Inc., invested the remaining $6,840,595 in exchange for
4,750,413 shares of common stock and warrants to purchase 2,375,206 shares of
common stock at an exercise price of $2.00 per share. All warrants issued under
the agreement have a term of seven years.
In June 2003, the Company raised gross proceeds of $1.5 million in a
private offering of 1,250,000 shares of common stock. In connection with the
offering the Company issued warrants to purchase 625,000 shares of the Company's
common stock to placement agents. The warrants are exercisable at a price of
$2.00 per share and have a term of five years.
In May 2003, we acquired substantially all of the assets of Plexus in
exchange for 1,950,000 shares of our common stock and the assumption of certain
liabilities, including promissory notes for loans we previously made to Plexus
for $50,000 and $20,000.
In December 2002 and January 2003, we completed a private placement of 34
units consisting of 1.7 million shares of common stock to a group of private
investors. The gross proceeds from the offering were $1,865,000 with net
proceeds to SIGA of approximately $1,682,000.
In October 2002, we completed a private placement of units consisting of
an aggregate of 1,037,500 shares of common stock and warrants to purchase
518,750 shares of common stock at an exercise price of $2.25 per share to a
group of private investors. The offering yielded net proceeds of approximately
$935,000.
See Item 12 for certain equity compensation information with respect to
equity compensation plans.
Other Transactions
In 2004, the Company reached a settlement agreement for breach of contract
with a founder of the Company, whereby the founder returned 40,938 common
shares, 150,000 warrants and $15,000 to the Company. The common shares were
retired by the Company. The Company recorded the $15,000 settlement amount as
other income.
Item 6. Selected Financial Data (in thousands, except share and per share data)
The following table sets forth selected financial information derived from our
audited consolidated financial statements as of and for the years ended December
31, 2004, 2003, 2002, 2001 and 2000.
Selling, general In-process
The year ended & Research and Patent research and Impairment of
December 31, Revenues administrative development preparation fees development intangible assets
- -------------- -------- ---------------- ------------ ---------------- ------------ -----------------
2004 $ 1,839 $ 4,042 $ 4,165 $ 393 $ 568 $ 2,118
2003 $ 732 $ 2,646 $ 2,943 $ 300 $ 137
2002 $ 344 $ 1,838 $ 1,766 $ 105
2001 $ 1,160 $ 2,571 $ 1,733 $ 117
2000 $ 483 $ 4,851 $ 2,609 $ 107
Weighted average
The year ended Loss per share: shares outstanding
December 31, Operating loss Net Loss basic & diluted basic & diluted
- -------------- -------------- -------- --------------- ------------------
2004 $ (9,448) $ (9,373) $ (0.40) 23,724,026
2003 $ (5,296) $ (5,277) $ (0.34) 15,717,138
2002 $ (3,365) $ (3,331) $ (0.32) 10,450,529
2001 $ (3,262) $ (3,730) $ (0.44) 8,499,961
2000 $ (7,084) $ (7,790) $ (1.08) 7,202,856
17
Total Net cash used
As of and for the year Cash & cash stockholders' in operating
ended December 31, Total assets equivalents equity activities
- ------------------ ------------ ----------- ------------- -------------
2004 $ 6,111 $ 2,021 $ 4,559 $ (4,890)
2003 $ 6,100 $ 1,441 $ 5,551 $ (5,332)
2002 $ 2,830 $ 2,069 $ 2,173 $ (2,648)
2001 $ 4,208 $ 3,148 $ 3,541 $ (2,944)
2000 $ 3,210 $ 1,707 $ 925 $ (3,938)
Item 7. Management's Discussion and Analysis of Financial Condition and Results
of Operations
The following discussion should be read in conjunction with our financial
statements and notes to those statements and other financial information
appearing elsewhere in this Annual Report. In addition to historical
information, the following discussion and other parts of this Annual Report
contain forward-looking information that involves risks and uncertainties.
Overview
Since our inception in December 1995, we have been principally engaged in
the research and development of novel products for the prevention and treatment
of serious infectious diseases, including products for use in the defense
against biological warfare agents such as Smallpox and Arenaviruses. The effort
to develop a drug for Smallpox is being aided by SBIR grants from the NIH
totaling approximately $5.8 million that were awarded in the third quarter of
2004 and a $1.6 million contract with the U.S. Army which began in January 2003.
The Arenavirus program is being supported by SBIR grants from the NIH totaling
approximately $6.3 million that were awarded in the third quarter of 2004.
Our anti-viral programs are designed to prevent or limit the replication
of the viral pathogen. Our anti-infectives programs are aimed at the
increasingly serious problem of drug resistance. These programs are designed to
block the ability of bacteria to attach to human tissue, the first step in the
infection process. We are also developing a technology for the mucosal delivery
of our vaccines which may allow the vaccines to activate the immune system at
the mucus lined surfaces of the body -- the mouth, the nose, the lungs and the
gastrointestinal and urogenital tracts -- the sites of entry for most infectious
agents.
We do not have commercial biomedical products, and we do not expect to
have such products for several years, if at all. We believe that we will need
additional funds to complete the development of our biomedical products. Our
plans with regard to these matters include continued development of our products
as well as seeking additional research support funds and financial arrangements.
Although we continue to pursue these plans, there is no assurance that we will
be successful in obtaining sufficient financing on terms acceptable to us. The
financial statements do not include any adjustments that might result from the
outcome of this uncertainty. Management believes it has sufficient funds and
projected cash flows to support operations beyond December 31, 2005.
Our biotechnology operations are run out of our research facility in
Corvallis, Oregon. We continue to seek to fund a major portion of our ongoing
antiviral, antibiotic and vaccine programs through a combination of government
grants and strategic alliances. While we have had success in obtaining strategic
alliances and grants, no assurance can be given that we will continue to be
successful in obtaining funds from these sources. Until additional relationships
are established, we expect to continue to incur significant research and
development costs and costs associated with the manufacturing of product for use
in clinical trials and pre-clinical testing. It is expected that general and
administrative costs, including patent and regulatory costs, necessary to
support clinical trials and research and development will continue to be
significant in the future.
To date, we have not marketed, or generated revenues from the commercial
sale of any products. Our biopharmaceutical product candidates are not expected
to be commercially available for several years, if at all.
18
Accordingly, we expect to incur operating losses for the foreseeable future.
There can be no assurance that we will ever achieve profitable operations.
Critical Accounting Estimates
The methods, estimates and judgments we use in applying our accounting
policies have a significant impact on the results we report in our financial
statements, which we discuss under the heading "Results of Operations" following
this section of our MD&A. Some of our accounting policies require us to make
difficult and subjective judgments, often as a result of the need to make
estimates of matters that are inherently uncertain. Our most critical accounting
estimates include the assessment of recoverability of goodwill, which impacts
goodwill impairments; assessment of recoverability of long-lived assets, which
primarily impacts operating income when we impair intangible assets. Below, we
discuss these policies further, as well as the estimates and judgments involved.
We also have other policies that we consider key accounting policies, such as
for revenue recognition; however, these policies do not require us to make
estimates or judgments that are difficult or subjective.
Significant Accounting Policies
The following is a brief discussion of the more significant accounting
policies and methods used by us in the preparation of our financial statements.
Note 2 of the Notes to the Consolidated Financial Statements includes a summary
of all of the significant accounting policies.
Revenue Recognition
The Company recognizes revenue from contract research and development and
research progress payments in accordance with SEC Staff Accounting Bulletin No.
104, Revenue Recognition, ("SAB 104"). In accordance with SAB 104, revenue is
recognized when persuasive evidence of an arrangement exists, delivery has
occurred, the fee is fixed and determinable, collectibility is reasonably
assured, contractual obligations have been satisfied and title and risk of loss
have been transferred to the customer. The Company recognizes revenue from
non-refundable up-front payments, not tied to achieving a specific performance
milestone, over the period which the Company is obligated to perform services or
based on the percentage of costs incurred to date, estimated costs to complete
and total expected contract revenue. Payments for development activities are
recognized as revenue is earned, over the period of effort. Substantive at-risk
milestone payments, which are based on achieving a specific performance
milestone, are recognized as revenue when the milestone is achieved and the
related payment is due, providing there is no future service obligation
associated with that milestone. In situations where the Company receives payment
in advance of the performance of services, such amounts are deferred and
recognized as revenue as the related services are performed.
Goodwill
Goodwill is recorded when the purchase price paid for an acquisition
exceeds the estimated fair value of the net identified tangible and intangible
assets acquired.
The Company performs an annual review in the fourth quarter of each year,
or more frequently if indicators of potential impairment exist, to determine if
the carrying value of the recorded goodwill is impaired. Goodwill impairment is
determined using a two-step approach in accordance with Statement of Financial
Accounting Standards No. 142 "Goodwill and Other Intangible Assets" ("SFAS
142"). The impairment review process compares the fair value of the reporting
unit in which goodwill resides to its carrying value. In 2004, the Company
operated as one business and one reporting unit. Therefore, the goodwill
impairment analysis was performed on the basis of the Company as a whole using
the market capitalization of the Company as an estimate of its fair value. The
estimated fair values might produce significantly different results if other
reasonable assumptions and estimates were to be used.
Identified Intangible Assets
Acquisition-related intangibles include acquired technology, customer
contracts, grants and covenants not to compete, and are amortized on a straight
line basis over periods ranging from 3.5-4 years.
19
In accordance with Statement of Financial Accounting Standards No. 144
"Accounting for the Impairment or Disposal of Long-Lived Assets" ("SFAS 144"),
the Company performs a review of its identified intangible assets to determine
if facts and circumstances exist which indicate that the useful life is shorter
than originally estimated or that the carrying amount of assets may not be
recoverable. If such facts and circumstances do exist, the Company assesses the
recoverability of identified intangible assets by comparing the projected
undiscounted net cash flows associated with the related asset or group of assets
over their remaining lives against their respective carrying amounts.
Impairment, if any, is based on the excess of the carrying amount over the fair
value of those assets.
Recent Accounting Pronouncements
In December 2004, the FASB issued SFAS No. 123R, "Share-Based Payment."
SFAS No. 123R requires employee stock options and rights to purchase shares
under stock participation plans to be accounted for under the fair value method,
and eliminates the ability to account for these instruments under the intrinsic
value method prescribed by APB Opinion No. 25, and allowed under the original
provisions of SFAS No. 123. SFAS No. 123R requires the use of an option pricing
model for estimating fair value, which is amortized to expense over the service
periods. The requirements of SFAS No. 123R are effective for fiscal periods
beginning after June 15, 2005. SFAS No. 123R allows for either prospective
recognition of compensation expense or retrospective recognition, which may be
back to the original issuance of SFAS No. 123 or only to interim periods in the
year of adoption. The Company is currently evaluating these transition methods.
In March 2004, the Emerging Issues Task Force issued EITF 03-06,
"Participating Securities and the Two-Class Method under FASB Statement No.
128". This statement provides additional guidance on the calculation and
disclosure requirements for earnings per share. The FASB concluded in EITF 03-06
that companies with multiple classes of common stock or participating
securities, as defined by SFAS No. 128, calculate and disclose earnings per
share based on the two-class method. The adoption of this statement did not have
an impact to our financial statements presentation as the Company is in a loss
position.
Results of Operations
The following table sets forth certain consolidated statements of income
data as a percentage of net revenue for the periods indicated:
2004 2003 2002
---------- ---------- ----------
Revenue 100% 100% 100%
---------- ---------- ----------
Selling, general and administrative 220% 362% 534%
Research and development 227% 402% 513%
Patent preparation fees 21% 41% 31%
In-process research and development 31% 0% 0%
Impairment of intangible assets 115% 19% 0%
---------- ---------- ----------
Operating loss 514% 723% 978%
Years ended December 31, 2004, 2003 and 2002
Revenues from grants and research and development contracts approximated
$1,839,200 for the year ended December 31, 2004 compared to $731,700 for the
year ended December 31, 2003. The approximate 151% increase is the result of the
award of two Phase I and two Phase II SBIR grants by the NIH during the third
quarter of 2004. The Phase II grants are for a two year period ending in the
third quarter of 2006. The total grant award was for approximately $12.1
million. For the year ended December 31, 2004 we recorded revenue of $1,049,600
from these grants. We also received a one year SBIR grant from the NIH for
$252,000 in August 2004 to support our Strep vaccine program. For the year ended
December 31, 2004 we recorded revenue of $85,600 from this grant. Revenue from
our contract with the U.S. Army was $425,100 for 2004; compared to $315,300 for
the year ended December 31, 2003. The approximate 35% increase was due to the
higher budget for work performed in 2004. For the year ended December 31, 2004
we received revenue of $254,800 from an SBIR grant for our DegP anti infective
that we
20
completed in the second quarter of 2004. For the year ended December 31, 2003 we
received $387,800 from this grant.
Revenue of $731,700 for the year ended December 31, 2003 was approximately
112% higher than revenue of $344,450 for the year ended December 31, 2002. The
increase for the year ended December 31, 2003 from the prior year reflects
$290,000 in revenue from the first year of our $1.6 million contract with the
U.S. Army for our work on the development of a Smallpox drug. Revenue from our
Phase II Small Business Innovation Research (SBIR) grant also increased. Revenue
from the SBIR grant for the year ended December 31, 2003 was approximately
$388,000, an approximate 44% increase over the year ended December 31, 2002. The
SBIR grant, which was a two year grant for a total of $865,000, ended on May 31,
2004.
Selling, general and administrative expenses for the year ended December
31, 2004 were $4,042,000 compared to expenses of $2,646,600 for the year ended
December 31, 2003. The increase of $1,395,400, or approximately 53%, was
primarily due to an increase of $628,000 in payroll expense, and a $693,000
increase in legal expenses. Payroll expenses increased by approximately 128%
primarily due to the addition of a Chief Executive Officer and a Vice President
- - Business Development, bonuses paid to employees, and the costs associated with
the termination of the Employment Agreement with our former President. The
increase in legal expenses of 272% from 2003 was the result of the costs
incurred to review and amend our corporate governance policies and procedures to
ensure compliance with the regulations promulgated under the Sarbanes Oxley Act
of 2002, as well as the NASDAQ stock market. Also contributing to the increase
in legal expenses were the costs incurred in connection with a potential
business combination, the sale of certain non-core vaccine assets, the hiring of
our new CEO, a legal action that we initiated against a former founder and the
work performed relative to the acquisition of certain assets and grants from
ViroPharma. Increases in travel expense, rent, amortization and filing fees were
offset by decreases in depreciation, insurance and miscellaneous expenses.
The $2,646,600 of selling, general and administrative expenses incurred
for the year ended December 31, 2003 represented an increase of approximately
44% from an expense of $1,838,500 for the year ended December 31, 2002. Of the
$808,100 increase, approximately $553,000 was the result of higher consulting
expenses associated with our marketing program to find additional sources of
government grant and contract funding and increased investor relations efforts.
Approximately $184,000 of the increase was the result of increased payroll
expense reflecting the administrative employees who were added in connection
with the acquisition of substantially all the assets of Plexus. In addition, the
year ended December 31, 2003 included non-cash expenses of approximately
$123,000 associated with the amortization of certain intangible assets acquired
in the Plexus transaction. These increases were partially offset by lower legal
and accounting fees. For the year ended December 31, 2002 legal and accounting
fees were approximately $176,000 higher than the expenses incurred in 2003 as
the result of work done in 2002 on a proposed merger.
Research and development expenses were $4,165,800 for the year ended
December 31, 2004; an increase of approximately 42% from the $2,942,800 of
expenses incurred for the year ended December 31, 2003. Amortization expense of
$635,900 represented approximately 35% of the increase. These expenses were the
result of the acquisition of certain assets from Plexus in 2003 and ViroPharma
in 2004. Payroll expenses increased approximately 28% to $1,654,000 for 2004
from $1,289,700 incurred in 2003. The increase was the result of the expansion
of staff to service the grants acquired from ViroPharma and bonuses paid to
employees. Sponsored research increased by approximately 117% in 2004 to
$486,000 from $223,500 in 2003. The increase was the result of payments made to
a Danish university for former Plexus programs, a payment made to TransTech
Pharma for work performed on an SBIR grant that was completed in the second
quarter and payments to Oregon State University for work on the strep grant
received in 2004. Expenses for lab supplies increased approximately 16% to
$472,890 from $407,076 as a result of accelerated development of our lead
product programs.
For the year ended December 31, 2003 research and development expenses
increased approximately 67% to $2,942,800 from $1,766,400 for the same period in
2002. Approximately $504,000 of the increase was the result of 64% higher
payroll expense caused by the addition of Plexus R&D personnel as well as
additional staffing for our ongoing Smallpox and anti-infectives programs. For
the year ended December 31, 2003 we recognized non-cash charges of approximately
$262,000 for the amortization of certain intangible assets acquired from Plexus;
no similar charges were recognized in the prior year. In addition, lab supply
expenses were approximately $400,000, an increase of approximately 83% in the
year ended December 31, 2003 from the prior year spending level of
21
approximately $219,000. The increase reflects increased activity on our Smallpox
and DegP programs. Sponsored research increased to approximately $315,000, an
82% increase from the prior year. The increase was due to payment for work being
performed on former Plexus programs at a Danish University.
All of our product programs are in the early stage of development. At this
stage of development, we cannot make estimates of the potential cost for any
program to be completed or the time it will take to complete the project. There
is a high risk of non-completion of any program because of the lead time to
program completion and uncertainty of the costs. Net cash inflows from any
products developed from these programs is at least one to three years away.
However, we could receive additional grants, contracts or technology licenses in
the short-term. The potential cash and timing is not known and we cannot be
certain if they will ever occur.
The risk of failure to complete any program is high, as each is in the
relatively early stage of development. Products for the biological warfare
defense market, such as the Smallpox anti-viral, could be available for sale in
one to three years. We believe the products directed toward this market are on
schedule. We expect the future research and development cost of this program to
increase as the potential products enter animal studies and safety testing.
Funds for future development will be partially paid for by NIH SBIR grants, the
contract we have with the U.S. Army, additional government funding and from
future financing. If we are unable to obtain additional federal grants and
contracts or funding in the required amounts, the development timeline for these
products would slow or possibly be suspended. The clinical trials for our Strep
vaccine through Phase II would be funded under an agreement with the NIH. The
time to market for this product should be several years from now because of the
nature of the FDA requirements for approval of a pediatric vaccine. We expect to
fund the development of the Strep vaccine beyond the Phase II clinical trials
through a corporate collaboration or from additional funding from debt or equity
financings. We do not yet have a corporate partner for this product and there is
no assurance that we will ever have one or that we will be able to raise the
funds needed to go forward. If the funding is not available or the clinical
trials are not successful, the program could be delayed or cancelled. We believe
this product program is on schedule. Delay or suspension of any of our programs
could have an adverse impact on our ability to raise funds in the future, enter
into collaborations with corporate partners or obtain additional federal funding
from contracts or grants.
Patent preparation expenses for the year ended December 31, 2004 were
$393,100 an approximate 31% increase from expenses of $300,500 incurred in 2003.
The increase was the result of increased costs arising from the Plexus and
ViroPharma asset acquisitions. The $300,500 of expense incurred in 2003 was an
approximate 187% increase over the $104,700 expense incurred in 2002, the result
of increased costs of patent work required on the intellectual property acquired
in the Plexus transaction, including foreign patent filings.
For the year ended December 31, 2004, as a result of the acquisition of
certain government grants and two early stage antiviral programs, Smallpox and
Arenavirus, targeting certain agents of biological warfare, from ViroPharma,
$568,329 was immediately expensed as purchased in-process research and
development ("IPRD"). The amount expensed as IPRD was attributed to technology
that has not reached technological feasibility and has no alternate future use.
The value allocated to IPRD was determined using the income approach that
included an excess earnings analysis reflecting the appropriate costs of capital
for the purchase. Estimates of future cash flows related to the IPRD were made
for both the Smallpox and Arenavirus programs. The aggregate discount rate of
approximately 55% utilized to discount the programs' cash flows were based on
consideration of the Company's weighted average cost of capital, as well as
other factors, including the stage of completion and the uncertainty of
technology advances for these programs. If the programs are not successful or
completed in a timely manner, the Company's product pricing and growth rates may
not be achieved and the Company may not realize the financial benefits expected
from the programs.
For the year ended December 31, 2004 we recorded a $2,118,200 non-cash
loss on impairment of assets. In December 2004, upon completion of the
ViroPharma transaction, integration of the related acquired programs into the
Company's operations, and the demonstrated antiviral activity of the Company's
lead smallpox compound against several mouse models of poxvirus disease, we
commenced an application process for additional government grants to support our
continued efforts under the Smallpox and Arenavirus antiviral programs. We
determined that significant efforts and resources will be necessary to
successfully continue the development efforts under these programs and decided
to allocate the necessary resources to support its commitment. As a result,
limited resources will be available for the development of future product
candidates that utilize the technology acquired from Plexus
22
in May 2003. These factors resulted in a significant reduction in forecasted
revenues related to that technology and a reduction in the future remaining
useful life, and triggered the related intangible asset impairment. The amount
of impairment recorded by us in December 2004 was determined using the two-step
process impairment review as required by SFAS 144. In the first step, we
compared the projected undiscounted net cash flows associated with the
technology acquired from Plexus over its remaining life against its carrying
amount. We determined that the carrying amount of the technology acquired from
Plexus exceeded its projected undiscounted cash flows. In the second step, we
estimated the fair value of the technology using the income method of valuation,
which included the use of estimated discounted cash flows. Based on our
assessment, we recorded a non-cash impairment charge of approximately $1.5
million in December 2004, which was included as a component of our operating
loss. In May 2004, we performed an impairment review of our intangible assets in
accordance with SFAS 144 in connection with the sale of certain intangible
assets from our immunological bioinformatics technology and certain non-core
vaccine development to a privately-held company, Pecos Labs, Inc. ("Pecos"). We
recorded an impairment charge of $307,000 to the grants transferred to Pecos and
$303,000 to the covenant not to compete with our President who was terminated
during the current year period.
For the year ended December 31, 2003, we incurred a loss on impairment of
assets as a result of taking a non-cash charge of $137,000 to the intangible
assets acquired in the Plexus transaction to reflect the termination of a
research agreement. No similar charge was incurred in 2002.
Total operating loss for the year ended December 31, 2004 was $9,448,300
compared to a loss of $5,294,900 for 2003. Of the current loss, $2,686,500 was
the result of non-cash charges incurred for the impairment of assets and
recognition of in-process research and development expense. Excluding these
expenses, the current year loss was approximately 28% higher than the prior
year. The increase in the loss was due to higher selling, general and
administrative expenses, higher research and development expenses and higher
patent costs as described in detail above. These increases were partially offset
by increased revenue.
Total operating loss for the year ended December 31, 2003 was $5,294,900,
an approximate 57% increase from the $3,365,100 loss incurred for the year ended
December 31, 2002. The increase in the loss is the result of higher selling,
general and administration expenses and research and development expenses as
described above, partially offset by higher revenues. Approximately 27% of the
increase in the net loss was the result of non-cash charges incurred in the year
ended December 31, 2003.
Other income was $75,000 in the year ended December 31, 2004 an increase
of approximately 311% from the $18,300 for the year ended December 31, 2003. The
increase was mainly due to interest income related to higher cash balances
during 2004 compared to 2003. In 2004 we also received other income of $15,000
as the result of the settlement of a legal action with a former founder.
Other income of $18,300 for the year ended December 31, 2003 was
approximately 46% lower than the $34,100 recognized for the year ended December
31, 2002 and reflected a reduction in interest income due to lower cash balances
and interest yields in the year ended December 31, 2003 compared to prior year.
Liquidity and Capital Resources
As of December 31, 2004 we had $2,020,938 in cash and cash equivalents. We
believe that these funds and our projected cash flows are sufficient to support
our operations beyond December 31, 2005, and that sufficient cash flows will be
available to meet our business objectives.
In August 2004, we acquired certain government grants and two early stage
antiviral programs, Smallpox and Arenavirus, targeting certain agents of
biological warfare from ViroPharma for a purchase price of $1,000,000 in cash
and 1,000,000 shares of our common stock. As part of the closing, we were
awarded Phase I and II SBIR grants from the NIH totaling approximately $12.1
million, which will be received over the next two years, for the development of
drugs for the treatment of Smallpox and Arenavirus as noted above.
In May 2004, we sold intangible assets from our immunological
bioinformatics technology and certain non-core vaccine development assets to a
privately-held company, Pecos Labs, Inc. ("Pecos") in exchange for 150,000
shares of Pecos common stock. As a result of this transaction, we performed an
impairment review of the intangible
23
assets and concluded that the carrying amount of certain transferred intangible
assets of $307,063 would not be recoverable. In addition, we terminated our
employment agreement with our President. We paid approximately $270,000 in
severance to our former President as well as accelerated vesting on 100,000
stock options that were due to vest in May 2004. No compensation charge was
recorded as the exercise price of the options was above the fair value market
price on the date of termination. In addition, we reduced the covenant not to
compete with our former President to one year from the date of termination. We
recognized $303,000 of impairment to the unamortized covenant not to compete
with our former President due to the reduction of the covenant to one year from
the date of termination.
In August 2003, we entered into an agreement with MacAndrews & Forbes
Holdings Inc. ("MacAndrews & Forbes"), a holding company of which the Company's
Chairman of the Board of Directors is Vice Chairman and a director. Upon
consummation of the agreement, MacAndrews & Forbes and its permitted assignees
invested an initial $1,000,000 in SIGA in exchange for 694,444 shares of our
common stock at a price of $1.44 per share and warrants to purchase 347,222
shares of common stock at an initial exercise price of $2.00 per share.
MacAndrews & Forbes and its permitted assignees also received an option,
exercisable through October 13, 2003, to invest up to an additional $9,000,000
in SIGA on the same terms. Upon exercise of the option in October 2003, we
received gross proceeds of $2,159,405 in exchange for 1,499,587 shares of common
stock at a price of $1.44 per share and warrants to purchase 749,794 shares of
common stock at an initial exercise price of $2.00 per share. In January 2004,
upon approval of the Company's shareholders, MacAndrews & Forbes and its
permitted assignees invested the remaining $6,840,595 in exchange for 4,750,413
shares of common stock and warrants to purchase 2,375,206 shares of common stock
at an exercise price of $2.00 per share. All warrants issued under the agreement
have a term of seven years.
In June 2003, the Company raised gross proceeds of $1.5 million in a
private offering of 1,250,000 shares of common stock. In connection with the
offering, the Company issued warrants to purchase 625,000 shares of the
Company's common stock to placement agents. The warrants are exercisable at a
price of $2.00 per share and have a term of five years.
In May 2003, we acquired substantially all of the assets of Plexus in
exchange for 1,950,000 shares of our common stock and the assumption of certain
liabilities, including promissory notes for loans we previously made to Plexus
for $50,000 and $20,000.
In December 2002 and January 2003, we completed a private placement of 34
units consisting of 1.7 million shares of common stock to a group of private
investors. The gross proceeds from the offering were $1,865,000 with net
proceeds to SIGA of approximately $1,682,000.
We anticipate that our current resources will be sufficient to finance our
currently anticipated needs for operating and capital expenditures approximately
beyond December 31, 2005. In addition, we will attempt to generate additional
working capital through a combination of collaborative agreements, strategic
alliances, research grants, equity and debt financing. However, no assurance can
be provided that additional capital will be obtained through these sources or,
if obtained, will be on commercially reasonable terms.
Our working capital and capital requirements will depend upon numerous
factors, including pharmaceutical research and development programs;
pre-clinical and clinical testing; timing and cost of obtaining regulatory
approvals; levels of resources that we devote to the development of
manufacturing and marketing capabilities; technological advances; status of
competitors; and our ability to establish collaborative arrangements with other
organizations.
24
Contractual Obligations, Commercial Commitments and Purchase Obligations
As of December 31, 2004, our purchase obligations are not material. We
lease certain facilities and office space under operating leases. Minimum future
rental commitments under operating leases having non-cancelable lease terms in
excess of one year are as follows:
Year ended December 31,
2005 $ 239,700
2006 255,400
2007 261,800
2008 133,200
2009 135,900
2010 22,700
-----------
Total $ 1,048,700
===========
Off-Balance Sheet Arrangements
SIGA does not have any off-balance sheet arrangements.
Risk Factors That May Affect Results of Operations and Financial Condition
This report contains forward-looking statements and other prospective
information relating to future events. These forward-looking statements and
other information are subject to risks and uncertainties that could cause our
actual results to differ materially from our historical results or currently
anticipated results including the following:
We have incurred operating losses since our inception and expect to incur net
losses and negative cash flow for the foreseeable future.
We incurred net losses of approximately $9.4 million, $5.3 million and
$3.3 million for the years ended December 31, 2004, 2003 and 2002, respectively.
As of December 31, 2004, 2003 and 2002, our accumulated deficit was
approximately $44.2 million, $34.8 million and $29.5 million, respectively. We
expect to continue to incur significant operating expenditures. We will need to
generate significant revenues to achieve and maintain profitability.
We cannot guarantee that we will achieve sufficient revenues for
profitability. Even if we do achieve profitability, we cannot guarantee that we
can sustain or increase profitability on a quarterly or annual basis in the
future. If revenues grow slower than we anticipate, or if operating expenses
exceed our expectations or cannot be adjusted accordingly, then our business,
results of operations and financial condition will be materially and adversely
affected. Because our strategy might include acquisitions of other businesses,
acquisition expenses and any cash used to make these acquisitions will reduce
our available cash.
Our business will suffer if we are unable to raise additional equity funding.
We continue to be dependent on our ability to raise money in the equity
markets. There is no guarantee that we will continue to be successful in raising
such funds. If we are unable to raise additional equity funds, we may be forced
to discontinue or cease certain operations. We currently have sufficient
operating capital to finance our operations beyond December 31, 2005. Our annual
operating needs vary from year to year depending upon the amount of revenue
generated through grants and licenses and the amount of projects we undertake,
as well as the amount of resources we expend, in connection with acquisitions
all of which may materially differ from year to year and may adversely affect
our business.
25
Our stock price is, and we expect it to remain, volatile, which could limit
investors' ability to sell stock at a profit.
The volatile price of our stock makes it difficult for investors to
predict the value of their investment, to sell shares at a profit at any given
time, or to plan purchases and sales in advance. A variety of factors may affect
the market price of our common stock. These include, but are not limited to:
o publicity regarding actual or potential clinical results relating to
products under development by our competitors or us;
o delay or failure in initiating, completing or analyzing pre-clinical or
clinical trials or the unsatisfactory design or results of these trials;
o achievement or rejection of regulatory approvals by our competitors or us;
o announcements of technological innovations or new commercial products by
our competitors or us;
o developments concerning proprietary rights, including patents;
o developments concerning our collaborations;
o regulatory developments in the United States and foreign countries;
o economic or other crises and other external factors;
o period-to-period fluctuations in our revenues and other results of
operations;
o changes in financial estimates by securities analysts; and
o sales of our common stock.
Additionally, because there is not a high volume of trading in our stock,
any information about SIGA in the media may result in significant volatility in
our stock price.
We will not be able to control many of these factors, and we believe that
period-to-period comparisons of our financial results will not necessarily be
indicative of our future performance.
In addition, the stock market in general, and the market for biotechnology
companies in particular, has experienced extreme price and volume fluctuations
that may have been unrelated or disproportionate to the operating performance of
individual companies. These broad market and industry factors may seriously harm
the market price of our common stock, regardless of our operating performance.
We are in various stages of product development and there can be no assurance of
successful commercialization.
In general, our research and development programs are at an early stage of
development. Our biological warfare defense products do not need human clinical
trials for approval by the FDA. We will need to perform two animal models and
provide safety data for a product to be approved. Our other products will be
subject to the approval guidelines under FDA regulatory requirements which
include a number of phases of testing in humans.
The FDA has not approved any of our biopharmaceutical product candidates.
Any drug candidates developed by us will require significant additional research
and development efforts, including extensive pre-clinical and clinical testing
and regulatory approval, prior to commercial sale. We cannot be sure our
approach to drug discovery will be effective or will result in the development
of any drug. We cannot expect that any drugs resulting from our research and
development efforts will be commercially available for many years, if at all.
We have limited experience in conducting pre-clinical testing and clinical
trials. Even if we receive initially positive pre-clinical or clinical results,
such results do not mean that similar results will be obtained in the later
stages of drug development, such as additional pre-clinical testing or human
clinical trials. All of our potential drug
26
candidates are prone to the risks of failure inherent in pharmaceutical product
development, including the possibility that none of our drug candidates will or
can:
o be safe, non-toxic and effective;
o otherwise meet applicable regulatory standards;
o receive the necessary regulatory approvals;
o develop into commercially viable drugs;
o be manufactured or produced economically and on a large scale;
o be successfully marketed;
o be reimbursed by government and private insurers; and
o achieve customer acceptance.
In addition, third parties may preclude us from marketing our drugs
through enforcement of their proprietary rights, that we are not aware of, or
third parties may succeed in marketing equivalent or superior drug products. Our
failure to develop safe, commercially viable drugs would have a material adverse
effect on our business, financial condition and results of operations.
Most of our immediately foreseeable future revenues are contingent upon grants
from the United States government, and collaborative and license agreements and
we may not achieve sufficient revenues from these agreements to attain
profitability.
Until and unless we successfully make a product, our ability to generate
revenues will largely depend on our ability to enter into additional
collaborative and license agreements with third parties and maintain the
agreements we currently have in place. Substantially all of our revenues for the
years ended December 31, 2004, 2003 and 2002, respectively, were derived from
revenues related to grants, contracts and license agreements. We will receive
little or no revenues under our collaborative agreements if our collaborators'
research, development or marketing efforts are unsuccessful, or if our
agreements are terminated early. Additionally, if we do not enter into new
collaborative agreements, we will not receive future revenues from new sources.
Our future revenue is substantially dependent on the continuing grant and
contract work being performed for the NIH under two major grants which expire in
September 2006 and the U.S. Army which expires at the end of December 2007.
These agreements are for specific work to be performed under the agreements and
could only be canceled by the other party thereto for non-performance by the
other party thereto.
Several factors will affect our future receipt of revenues from
collaborative arrangements, including the amount of time and effort expended by
our collaborators, the timing of the identification of useful drug targets and
the timing of the discovery and development of drug candidates. Under our
existing agreements, we may not earn significant milestone payments until our
collaborators have advanced products into clinical testing, which may not occur
for many years, if at all.
We have material agreements with the following collaborators:
o National Institutes of Health. Under our collaborative agreement
with the NIH we have received SBIR Grants totaling approximately
$12.1 million in 2004. The term of these grants expire in September
2006. We are paid as the work is performed and the agreement can be
cancelled for non-performance. We also have an agreement whereby the
NIH is required to conduct and pay for the clinical trials of our
strep vaccine product through phase II human trials. The NIH can
terminate the agreement on 60 days written notice. If terminated, we
receive copies of all data, reports and other information related to
the trials. If terminated, we would have to find another source of
funds to continue to conduct the trials. We are current in all our
obligations under our agreements.
o The Rockefeller University. The term of our agreement with
Rockefeller is for the duration of the patents and a number of
pending patents. As we do not currently know when any patents
pending or
27
future patents will expire, we cannot at this time definitively
determine the term of this agreement. The agreement can be
terminated earlier if we are in breach of the provisions of the
agreement and do not cure the breach in the allowed cure period. We
are current in all obligations under the contract.
o Oregon State University ("OSU"). OSU is a signatory of our agreement
with Rockefeller. The term of this agreement is for the duration of
the patents and a number of pending patents. As we do not currently
know when any patents pending or future patents will expire, we
cannot at this time definitively determine the term of this
agreement. The agreement can be terminated earlier if we are in
breach of the provisions of the agreement and do not cure the breach
in the allowed cure period. We are current in all obligations under
the contract. We have also entered into a subcontract agreement with
OSU for us to perform work under a grant OSU has from the NIH. The
subcontract agreement was renewable annually and the current terms
expired on August 31, 2003. Work on this agreement was completed in
2003.
o Wyeth. Our license agreement expires on the earlier of June 30, 2007
or the last to expire patent that we have sub-licensed to them.
Wyeth has the right to terminate the agreement on 90 days written
notice. If terminated, all rights granted to Wyeth will revert to
us, except for any compound identified by Wyeth prior to the date of
termination and subject to the milestones and royalty obligations of
the agreement.
o Washington University. We have licensed certain technology from
Washington under a non-exclusive license agreement. The term of our
agreement with Washington is for the duration of the patents and a
number of pending patents. As we do not currently know when any
patents pending or future patents will expire, we cannot at this
time definitively determine the term of this agreement. The
agreement cannot be terminated unless we fail to pay our share of
the joint patent costs for the technology licensed. We have
currently met all our obligations under this agreement.
o Regents of the University of California. We have licensed certain
technology from Regents under an exclusive license agreement. We are
required to pay minimum royalties under this agreement. This
agreement is related to our agreement with Wyeth and expires at the
same time as that agreement. It can be cancelled earlier if we
default on our obligations or if Wyeth cancels its agreement with
SIGA and we are not able to find a replacement for Wyeth. We have
currently met all our obligations under this agreement.
o U.S. Army Medical Research Acquisition Activity. In December 2002,
we entered into a four years contract with the U.S. Army Medical
Research Acquisition Activity (USAMRAA) to develop a drug to treat
Smallpox. We are current in all our obligations under our agreement.
o TransTech Pharma, Inc. Under our collaborative agreement with
TransTech Pharma, TransTech Pharma is required to collaborate with
us on the discovery, optimization and development of lead compounds
to therapeutic agents. We and TransTech Pharma have agreed to share
the costs of development and revenues generated from licensing and
profits from any commercialized products sales. The agreement will
be in effect until terminated by the parties or upon cessation of
research or sales of all products developed under the agreement. We
are current in all obligations under this agreement.
The biopharmaceutical market in which we compete and will compete is highly
competitive.
The biopharmaceutical industry is characterized by rapid and significant
technological change. Our success will depend on our ability to develop and
apply our technologies in the design and development of our product candidates
and to establish and maintain a market for our product candidates. There also
are many companies, both public and private, including major pharmaceutical and
chemical companies, specialized biotechnology firms, universities and other
research institutions engaged in developing pharmaceutical and biotechnology
products. Many of these companies have substantially greater financial,
technical, research and development, and human resources than us. Competitors
may develop products or other technologies that are more effective than any that
are being
28
developed by us or may obtain FDA approval for products more rapidly than us. If
we commence commercial sales of products, we still must compete in the
manufacturing and marketing of such products, areas in which we have no
experience. Many of these companies also have manufacturing facilities and
established marketing capabilities that would enable such companies to market
competing products through existing channels of distribution. Two companies with
similar profiles are VaxGen, Inc., which is developing vaccines against anthrax,
Smallpox and HIV/AIDS; and Avant Immunotherapeutics, Inc., which has vaccine
programs for agents of biological warfare.
Because we must obtain regulatory clearance to test and market our products in
the United States, we cannot predict whether or when we will be permitted to
commercialize our products.
A pharmaceutical product cannot be marketed in the U.S. until it has
completed rigorous pre-clinical testing and clinical trials and an extensive
regulatory clearance process implemented by the FDA. Pharmaceutical products
typically take many years to satisfy regulatory requirements and require the
expenditure of substantial resources depending on the type, complexity and
novelty of the product.
Before commencing clinical trials in humans, we must submit and receive
clearance from the FDA by means of an Investigational New Drug ("IND")
application. Institutional review boards and the FDA oversee clinical trials and
such trials:
o must be conducted in conformance with the FDA's good laboratory
practice regulations;
o must meet requirements for institutional review board oversight;
o must meet requirements for informed consent;
o must meet requirements for good clinical and manufacturing
practices;
o are subject to continuing FDA oversight;
o may require large numbers of test subjects; and
o may be suspended by us or the FDA at any time if it is believed that
the subjects participating in these trials are being exposed to
unacceptable health risks or if the FDA finds deficiencies in the
IND application or the conduct of these trials.
Before receiving FDA clearance to market a product, we must demonstrate
that the product is safe and effective on the patient population that will be
treated. Data we obtain from preclinical and clinical activities are susceptible
to varying interpretations that could delay, limit or prevent regulatory
clearances. Additionally, we have limited experience in conducting and managing
the clinical trials and manufacturing processes necessary to obtain regulatory
clearance.
If regulatory clearance of a product is granted, this clearance will be
limited only to those states and conditions for which the product is
demonstrated through clinical trials to be safe and efficacious. We cannot
ensure that any compound developed by us, alone or with others, will prove to be
safe and efficacious in clinical trials and will meet all of the applicable
regulatory requirements needed to receive marketing clearance.
If our technologies or those of our collaborators are alleged or found to
infringe the patents or proprietary rights of others, we may be sued or have to
license those rights from others on unfavorable terms.
Our commercial success will depend significantly on our ability to operate
without infringing the patents and proprietary rights of third parties. Our
technologies, along with our licensors' and our collaborators' technologies, may
infringe the patents or proprietary rights of others. If there is an adverse
outcome in litigation or an interference to determine priority or other
proceeding in a court or patent office, then we, or our collaborators and
licensors, could be subjected to significant liabilities, required to license
disputed rights from or to other parties and/or required to cease using a
technology necessary to carry out research, development and commercialization.
At present we are unaware of any or potential infringement claims against our
patent portfolio.
The costs to establish the validity of patents, to defend against patent
infringement claims of others and to assert infringement claims against others
can be expensive and time consuming, even if the outcome is favorable.
29
An outcome of any patent prosecution or litigation that is unfavorable to us or
one of our licensors or collaborators may have a material adverse effect on us.
We could incur substantial costs if we are required to defend ourselves in
patent suits brought by third parties, if we participate in patent suits brought
against or initiated by our licensors or collaborators or if we initiate such
suits. We may not have sufficient funds or resources in the event of litigation.
Additionally, we may not prevail in any such action.
Any conflicts resulting from third-party patent applications and patents
could significantly reduce the coverage of the patents owned, optioned by or
licensed to us or our collaborators and limit our ability or that of our
collaborators to obtain meaningful patent protection. If patents are issued to
third parties that contain competitive or conflicting claims, we, our licensors
or our collaborators may be legally prohibited from researching, developing or
commercializing of potential products or be required to obtain licenses to these
patents or to develop or obtain alternative technology. We, our licensors and/or
our collaborators may be legally prohibited from using patented technology, may
not be able to obtain any license to the patents and technologies of third
parties on acceptable terms, if at all, or may not be able to obtain or develop
alternative technologies.
In addition, like many biopharmaceutical companies, we may from time to
time hire scientific personnel formerly employed by other companies involved in
one or more areas similar to the activities conducted by us. We and/or these
individuals may be subject to allegations of trade secret misappropriation or
other similar claims as a result of their prior affiliations.
Our ability to compete may decrease if we do not adequately protect our
intellectual property rights.
Our commercial success will depend in part on our and our collaborators'
ability to obtain and maintain patent protection for our proprietary
technologies, drug targets and potential products and to effectively preserve
our trade secrets. Because of the substantial length of time and expense
associated with bringing potential products through the development and
regulatory clearance processes to reach the marketplace, the pharmaceutical
industry places considerable importance on obtaining patent and trade secret
protection. The patent positions of pharmaceutical and biotechnology companies
can be highly uncertain and involve complex legal and factual questions. No
consistent policy regarding the breadth of claims allowed in biotechnology
patents has emerged to date. Accordingly, we cannot predict the type and breadth
of claims allowed in these patents.
We have licensed the rights to eight issued U.S. patents and three issued
European patents. These patents have varying lives and they are related to the
technology licensed from Rockefeller University for the Strep and Gram-positive
products. We have one additional patent application in the U.S. and one
application in Europe relating to this technology. We are joint owner with
Washington University of seven issued patents in the U.S. and one in Europe. In
addition, there are four co-owned U.S. patent applications. These patents are
for the technology used for the gram-negative product opportunities. We are also
exclusive owner of one U.S. patent and three U.S. patent applications. One of
these U.S. patent applications relates to our DegP product opportunities.
We included a summary of out patent positions as of December 31, 2004 in
Part I, Item 1 of this document.
We also rely on copyright protection, trade secrets, know-how, continuing
technological innovation and licensing opportunities. In an effort to maintain
the confidentiality and ownership of trade secrets and proprietary information,
we require our employees, consultants and some collaborators to execute
confidentiality and invention assignment agreements upon commencement of a
relationship with us. These agreements may not provide meaningful protection for
our trade secrets, confidential information or inventions in the event of
unauthorized use or disclosure of such information, and adequate remedies may
not exist in the event of such unauthorized use or disclosure.
We may have difficulty managing our growth.
We expect to experience growth in the number of our employees and the
scope of our operations. This growth has placed, and may continue to place, a
significant strain on our management and operations. Our ability to manage this
growth will depend upon our ability to broaden our management team and our
ability to attract, hire and
30
retain skilled employees. Our success will also depend on the ability of our
officers and key employees to continue to implement and improve our operational
and other systems and to hire, train and manage our employees.
Our activities involve hazardous materials and may subject us to environmental
regulatory liabilities.
Our biopharmaceutical research and development involves the controlled use
of hazardous and radioactive materials and biological waste. We are subject to
federal, state and local laws and regulations governing the use, manufacture,
storage, handling and disposal of these materials and certain waste products.
Although we believe that our safety procedures for handling and disposing of
these materials comply with legally prescribed standards, the risk of accidental
contamination or injury from these materials cannot be completely eliminated. In
the event of an accident, we could be held liable for damages, and this
liability could exceed our resources. The research and development activities of
our company do not produce any unusual hazardous products. We do use small
amounts of 32P, 35S and 3H, which are stored, used and disposed of in accordance
with Nuclear Regulatory Commission ("NRC") regulations. We maintain liability
insurance in the amount of approximately $5,000,000 and we believe this should
be sufficient to cover any contingent losses.
We believe that we are in compliance in all material respects with
applicable environmental laws and regulations and currently do not expect to
make material additional capital expenditures for environmental control
facilities in the near term. However, we may have to incur significant costs to
comply with current or future environmental laws and regulations.
Our potential products may not be acceptable in the market or eligible for third
party reimbursement resulting in a negative impact on our future financial
results.
Any products successfully developed by us or our collaborative partners
may not achieve market acceptance. The antibiotic products which we are
attempting to develop will compete with a number of well-established traditional
antibiotic drugs manufactured and marketed by major pharmaceutical companies.
The degree of market acceptance of any of our products will depend on a number
of factors, including:
o the establishment and demonstration in the medical community of the
clinical efficacy and safety of such products,
o the potential advantage of such products over existing treatment
methods, and
o reimbursement policies of government and third-party payors.
Physicians, patients or the medical community in general may not accept or
utilize any products that we or our collaborative partners may develop. Our
ability to receive revenues and income with respect to drugs, if any, developed
through the use of our technology will depend, in part, upon the extent to which
reimbursement for the cost of such drugs will be available from third-party
payors, such as government health administration authorities, private health
care insurers, health maintenance organizations, pharmacy benefits management
companies and other organizations. Third-party payors are increasingly disputing
the prices charged for pharmaceutical products. If third-party reimbursement was
not available or sufficient to allow profitable price levels to be maintained
for drugs developed by us or our collaborative partners, it could adversely
affect our business.
If our products harm people, we may experience product liability claims that may
not be covered by insurance.
We face an inherent business risk of exposure to potential product
liability claims in the event that drugs we develop are alleged to cause adverse
effects on patients. Such risk exists for products being tested in human
clinical trials, as well as products that receive regulatory approval for
commercial sale. We may seek to obtain product liability insurance with respect
to drugs we and/or or our collaborative partners develop. However, we may not be
able to obtain such insurance. Even if such insurance is obtainable, it may not
be available at a reasonable cost or in a sufficient amount to protect us
against liability.
31
We may be required to perform additional clinical trials or change the labeling
of our products if we or others identify side effects after our products are on
the market, which could harm sales of the affected products.
If we or others identify side effects after any of our products, if any,
after they are on the market, or if manufacturing problems occur:
o regulatory approval may be withdrawn;
o reformulation of our products, additional clinical trials, changes
in labeling of our products may be required;
o changes to or re-approvals of our manufacturing facilities may be
required;
o sales of the affected products may drop significantly;
o our reputation in the marketplace may suffer; and
o lawsuits, including class action suits, may be brought against us.
Any of the above occurrences could harm or prevent sales of the affected
products or could increase the costs and expenses of commercializing and
marketing these products.
The manufacture of genetically engineered commensals is a time-consuming and
complex process which may delay or prevent commercialization of our products, or
may prevent our ability to produce an adequate volume for the successful
commercialization of our products.
Although our management believes that we have the ability to acquire or
produce quantities of genetically engineered commensals sufficient to support
our present needs for research and our projected needs for our initial clinical
development programs, management believes that improvements in our manufacturing
technology will be required to enable us to meet the volume and cost
requirements needed for certain commercial applications of commensal products.
Products based on commensals have never been manufactured on a commercial scale.
The manufacture of all of our products will be subject to current GMP
requirements prescribed by the FDA or other standards prescribed by the
appropriate regulatory agency in the country of use. There can be no assurance
that we will be able to manufacture products, or have products manufactured for
us, in a timely fashion at acceptable quality and prices, that we or third party
manufacturers can comply with GMP, or that we or third party manufacturers will
be able to manufacture an adequate supply of product.
Healthcare reform and controls on healthcare spending may limit the price we
charge for any products and the amounts thereof that we can sell.
The U.S. federal government and private insurers have considered ways to
change, and have changed, the manner in which healthcare services are provided
in the U.S. Potential approaches and changes in recent years include controls on
healthcare spending and the creation of large purchasing groups. In the future,
the U.S. government may institute further controls and limits on Medicare and
Medicaid spending. These controls and limits might affect the payments we could
collect from sales of any products. Uncertainties regarding future healthcare
reform and private market practices could adversely affect our ability to sell
any products profitably in the U.S. At present, we do not foresee any changes in
FDA regulatory policies that would adversely affect our development programs.
The future issuance of preferred stock may adversely affect the rights of the
holders of our common stock.
Our certificate of incorporation allows our Board of Directors to issue up
to 10,000,000 shares of preferred stock and to fix the voting powers,
designations, preferences, rights and qualifications, limitations or
restrictions of
32
these shares without any further vote or action by the stockholders. The rights
of the holders of common stock will be subject to, and could be adversely
affected by, the rights of the holders of any preferred stock that we may issue
in the future. The issuance of preferred stock, while providing desirable
flexibility in connection with possible acquisitions and other corporate
purposes, could have the effect of making it more difficult for a third party to
acquire a majority of our outstanding voting stock, thereby delaying, deferring
or preventing a change in control.
Concentration of ownership of our capital stock could delay or prevent change of
control.
Our directors, executive officers and principal stockholders beneficially
own a significant percentage of our common stock and preferred stock. They also
have, through the exercise or conversion of certain securities, the right to
acquire additional common stock. As a result, these stockholders, if acting
together, have the ability to significantly influence the outcome of corporate
actions requiring shareholder approval. Additionally, this concentration of
ownership may have the effect of delaying or preventing a change in control of
SIGA. At December 31, 2004, Directors, Officers and principal stockholders
beneficially owned approximately 48.1% of our stock.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
None
33
Item 8. Financial Statements and Supplementary Data
Index to the Consolidated Financial Statements
Report of Independent Registered Public Accounting Firm............................................35
Consolidated Balance Sheets as of December 31, 2004 and 2003.......................................36
Consolidated Statements of Operations for the years ended December 31, 2004, 2003 and 2002.........37
Consolidated Statements of Changes in Stockholders' Equity for the years ended December 31,
2004, 2003 and 2002.............................................................................38
Consolidated Statements of Cash Flows for the years ended December 31, 2004, 2003 and 2002.........40
Notes to Consolidated Financial Statements.........................................................41
34
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of SIGA Technologies, Inc.:
In our opinion, the accompanying consolidated balance sheets and the related
consolidated statements of operations, of changes in stockholders' equity and of
cash flows present fairly, in all material respects, the financial position of
SIGA Technologies, Inc. at December 31, 2004 and 2003, and the results of their
operations and their cash flows for each of the three years in the period ended
December 31, 2004 in conformity with accounting principles generally accepted in
the United States of America. These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on
these financial statements based on our audits. We conducted our audits of these
statements in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant estimates
made by management, and evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
/s/ PRICEWATERHOUSECOOPERS LLP
New York, New York
February 22, 2005
35
SIGA TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEETS
As of December 31, 2004 and 2003
December 31, December 31,
2004 2003
------------ ------------
ASSETS
Current assets
Cash and cash equivalents ..................................................... $ 2,020,938 $ 1,440,724
Accounts receivable ........................................................... 108,904 38,786
Prepaid expenses .............................................................. 278,547 50,338
------------ ------------
Total current assets ......................................................... 2,408,389 1,529,848
Property, plant and equipment, net ............................................ 508,015 379,046
Goodwill ...................................................................... 898,334 898,334
Intangible assets, net ........................................................ 2,114,297 3,117,357
Other assets .................................................................. 181,725 174,995
------------ ------------
Total assets ................................................................. $ 6,110,760 $ 6,099,580
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable .............................................................. $ 1,148,277 $ 353,051
Accrued expenses and other .................................................... 403,072 195,181
------------ ------------
Total liabilities ............................................................ 1,551,349 548,232
Commitments and contingencies
Stockholders' equity
Series A convertible preferred stock ($.0001 par value, 10,000,000 shares
authorized, 68,038 and 81,366 issued and outstanding at December 31, 2004
and December 31, 2003, respectively) .......................................... 58,672 72,666
Common stock ($.0001 par value, 50,000,000 shares authorized,
24,500,648 and 18,676,851 issued and outstanding at December 31, 2004
and December 31, 2003, respectively) ........................................ 2,450 1,868
Additional paid-in capital .................................................... 48,679,650 40,284,856
Accumulated deficit ........................................................... (44,181,361) (34,808,042)
------------ ------------
Total stockholders' equity ................................................... 4,559,411 5,551,348
------------ ------------
Total liabilities and stockholders' equity ................................... $ 6,110,760 $ 6,099,580
============ ============
The accompanying notes are an integral part of these financial statements.
36
SIGA TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
For the Years Ended December 31, 2004, 2003 and 2002
Year Ended December 31,
2004 2003 2002
------------ ------------ ------------
Revenues
Research and development ................................ $ 1,839,182 $ 731,743 $ 344,450
------------ ------------ ------------
Operating expenses
Selling, general and administrative ..................... 4,041,973 2,646,586 1,838,470
Research and development ................................ 4,165,849 2,942,809 1,766,368
Patent preparation fees ................................. 393,100 300,494 104,700
In-process research and development ..................... 568,329 -- --
Impairment of intangible assets ......................... 2,118,219 136,750 --
------------ ------------ ------------
Total operating expenses ............................. 11,287,470 6,026,639 3,709,538
------------ ------------ ------------
Operating loss ....................................... (9,448,288) (5,294,896) (3,365,088)
Other income, net ............................................ 74,969 18,256 34,061
------------ ------------ ------------
Net loss ............................................. $ (9,373,319) $ (5,276,640) $ (3,331,027)
Deemed dividend related to beneficial conversion feature ..... -- -- 29,200
------------ ------------ ------------
Net loss applicable to common shareholders ........... $ (9,373,319) $ (5,276,640) $ (3,360,227)
============ ============ ============
Weighted average shares outstanding: basic and diluted ....... 23,724,026 15,717,138 10,450,529
============ ============ ============
Net loss per share: basic and diluted ........................ $ (0.40) $ (0.34) $ (0.32)
============ ============ ============
The accompanying notes are an integral part of these financial statements.
37
SIGA TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
For the Years Ended December 31, 2004, 2003 and 2002
Series A
Convertible
Preferred Stock Common Stock
------------------------ -----------------------
Shares Amount Shares Amount
Balance at January 1, 2002 379,294 $ 398,441 10,139,553 $ 1,016
Net proceeds from issuance of common stock ($1.00 to $1.09 per share) 2,737,500 274
Issuance of common shares upon exercise of stock options 25,000 3
Issuance of preferred stock to settle dividends payable 31,466 45,233
Amortization of deferred compensation
Stock options issued to non-employee
Deemed dividend related to beneficial conversion feature
Net loss
---------- ---------- ---------- ----------
Balance at December 31, 2002 410,760 443,674 12,902,053 1,293
========== ========== ========== ==========
Net proceeds from issuance of common stock ($1.20 to $1.44 per share) 3,444,031 344
Issuance of common stock upon acquisition 1,950,000 195
Issuance of stock options and warrants upon acquisition
Issuance of common stock upon exercise of stock options and warrants 27,582 3
Conversion of preferred stock for common stock (353,185) (371,008) 353,185 33
Issuance of preferred stock for anti-dilution 23,791
Stock options issued to non-employee
Receipt of stock subscriptions outstanding
Net loss
---------- ---------- ---------- ----------
Balance at December 31, 2003 81,366 $ 72,666 18,676,851 $ 1,868
========== ========== ========== ==========
Net proceeds from issuance of common stock ($1.44 per share) 4,750,413 475
Issuance of common stock upon exercise of stock options and warrants 70,994 7
Conversion of preferred stock for common stock (13,328) (13,994) 13,328 1
Stock issued in acquisition of intangible assets 1,000,000 100
Common stock retired upon settlement agreement with a founder (40,938) (4)
Stock issued for services 30,000 3
Net loss
---------- ---------- ---------- ----------
Balance at December 31, 2004 68,038 $ 58,672 24,500,648 $ 2,450
========== ========== ========== ==========
The accompanying notes are an integral part of these financial statements.
(Continued)
38
SIGA TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
For the Years Ended December 31, 2004, 2003 and 2002
Additional Deferred Stock Total
Paid-in Comp- Subscriptions Accumulated Stockholders'
Capital ensation Outstanding Deficit Equity
------------ ------------ ------------- -------------- ------------
Balance at January 1, 2002 $ 29,348,786 $ (35,583) $ -- $ (26,171,175) $ 3,541,485
Net proceeds from issuance of common stock
($1.00 to $1.09 per share) 2,559,924 (791,940) 1,768,258
Issuance of common shares upon exercise of stock options 28,093 28,096
Issuance of preferred stock to settle dividends payable 45,233
Amortization of deferred compensation 35,583 35,583
Stock options issued to non-employee 85,458 85,458
Deemed dividend related to beneficial conversion feature 29,200 (29,200)
Net loss (3,331,027) (3,331,027)
------------ ------------ ------------ -------------- ------------
Balance at December 31, 2002 32,051,461 -- (791,940) (29,531,402) 2,173,086
============ ============ ============ ============== ============
Net proceeds from issuance of common stock
($1.20 to $1.44 per share) 4,171,652 4,171,996
Issuance of common stock upon acquisition 3,408,805 3,409,000
Issuance of stock options and warrants upon acquisition 255,873 255,873
Issuance of common stock upon exercise of
stock options and warrants 24,715 24,718
Conversion of preferred stock for common stock 370,975 --
Issuance of preferred stock for anti-dilution --
Stock options issued to non-employee 1,375 1,375
Receipt of stock subscriptions outstanding 791,940 791,940
Net loss (5,276,640) (5,276,640)
------------ ------------ ------------ -------------- ------------
Balance at December 31, 2003 $ 40,284,856 $ -- $ -- $ (34,808,042) $ 5,551,348
============ ============ ============ ============== ============
Net proceeds from issuance of common stock
($1.44 per share) 6,784,131 6,784,606
Issuance of common stock upon exercise of stock
options and warrants 69,369 69,376
Conversion of preferred stock for common stock 13,993 --
Stock issued in acquisition of intangible assets 1,479,900 1,480,000
Common stock retired upon settlement agreement
with a founder 4 --
Stock issued for services 47,397 -- 47,400
Net loss (9,373,319) (9,373,319)
------------ ------------ ------------ -------------- ------------
Balance at December 31, 2004 $ 48,679,650 $ -- $ -- $ (44,181,361) $ 4,559,411
============ ============ ============ ============== ============
The accompanying notes are an integral part of these financial statements.
39
SIGA TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Years Ended December 31, 2004, 2003 and 2002
Year Ended December 31,
2004 2003 2002
------------ ------------ ------------
Cash flows from operating activities:
Net loss ............................................................ $ (9,373,319) $ (5,276,640) $ (3,331,027)
Adjustments to reconcile net loss to net
cash used in operating activities:
In-process research and development ............................... 568,329 -- --
Impairment of intangible assets ................................... 2,118,219 136,750 --
Bad debt expense .................................................. -- 26,000 --
Depreciation ...................................................... 221,719 354,667 317,032
Amortization of intangible assets ................................. 832,534 384,893 --
Stock based compensation .......................................... 47,400 1,375 121,041
Changes in assets and liabilities:
Accounts receivable ............................................. (70,118) (4,635) (5,151)
Prepaid expenses ................................................ (231,210) 53,889 49,189
Other assets .................................................... (6,729) (10,827) (16,295)
Accounts payable and accrued expenses ........................... 1,003,117 (997,640) 216,926
------------ ------------ ------------
Net cash used in operating activities ........................... (4,890,058) (5,332,168) (2,648,285)
------------ ------------ ------------
Cash flows from investing activities:
Acquisition of intangible assets .................................... (1,033,022) -- --
Capital expenditures ................................................ (350,688) (273,560) (46,235)
------------ ------------ ------------
Net cash flow used in investing activities ...................... (1,383,710) (273,560) (46,235)
------------ ------------ ------------
Cash flows from financing activities:
Net proceeds from issuance of common stock .......................... 6,784,607 4,171,996 1,768,258
Receipts of stock subscriptions outstanding ......................... -- 791,940 --
Proceeds from exercise of options and warrants ...................... 69,375 24,718 28,096
Principal payments on capital lease obligations ..................... -- (11,206) (180,990)
------------ ------------ ------------
Net cash provided from financing activities ..................... 6,853,982 4,977,448 1,615,364
------------ ------------ ------------
Net increase (decrease) in cash and cash equivalents ................ 580,214 (628,280) (1,079,156)
Cash and cash equivalents at beginning of period .................... 1,440,724 2,069,004 3,148,160
------------ ------------ ------------
Cash and cash equivalents at end of period .......................... $ 2,020,938 $ 1,440,724 $ 2,069,004
============ ============ ============
Non-cash supplemental information:
Conversion of preferred stock to common stock ....................... $ 13,994 $ 371,008 $ --
Transfer of intangible assets for investment in Pecos Labs, Inc. .... $ 15,000 $ -- $ --
Shares issued for acquisition of intangible assets .................. $ 1,480,000 $ -- $ --
Shares issued for services .......................................... $ 47,400 $ -- $ --
Supplemental information of business acquired:
Fair value of assets acquired:
Equipment ......................................................... $ -- $ 27,711 $ --
Intangible assets ................................................. -- 3,639,000 --
Goodwill .......................................................... -- 898,334 --
Less, liabilities assumed and non-cash consideration:
Current liabilities ............................................... -- (494,142) --
Stock issued ...................................................... -- (3,409,000) --
Stock options and warrants issued ................................. -- (255,873) --
Accrued acquisition costs ......................................... -- (460,030) --
The accompanying notes are an integral part of these financial statements.
40
SIGA TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Organization and Basis of Presentation
Organization
SIGA Technologies, Inc. ("SIGA" or the "Company") is engaged in the discovery,
development and commercialization of vaccines, antibiotics, and novel
anti-infectives for the prevention and treatment of infectious diseases,
including products for use in defense against biological warfare agents. SIGA
applies bacterial and viral genomics in the design and development of its
products. The Company's product development programs emphasize the increasingly
serious problem of drug resistant bacteria and emerging pathogens.
Basis of presentation
The accompanying financial statements have been prepared on a basis which
assumes that the Company will continue as a going concern and which contemplates
the realization of assets and the satisfaction of liabilities and commitments in
the normal course of business. The Company has incurred cumulative net losses
and expects to incur additional losses to perform further research and
development activities. The Company does not have commercial products and has
limited capital resources. Management's plans with regard to these matters
include continued development of its products as well as seeking additional
research support funds and financial arrangements. Although management continues
to pursue these plans, there is no assurance that the Company will be successful
in obtaining sufficient financing on terms acceptable to the Company. Management
believes that its cash flows are sufficient to support its operations beyond
December 31, 2005, and that sufficient cash flows will be available to meet the
Company's business objectives. In the event that sufficient funds are not
available, the Company will need to postpone or discontinue planned operations
and projects. Continuance of the Company as a going concern is dependent upon,
among other things, the success of the Company's research and development
programs and the Company's ability to obtain adequate financing. The financial
statements do not include any adjustments relating to the recoverability of the
carrying amount of recorded assets and liabilities that might result from the
outcome of these uncertainties.
2. Summary of Significant Accounting Policies
Use of Estimates
The financial statements and related disclosures are prepared in conformity with
accounting principles generally accepted in the United States of America.
Management is required to make estimates and assumptions that affect the
reported amounts of assets and liabilities, the disclosure of contingent assets
and liabilities at the date of the financial statements and revenue and expenses
during the period reported. These estimates include the realization of deferred
tax assets, useful lives and impairment of tangible and intangible assets, and
the value of options and warrants granted by the Company. Estimates and
assumptions are reviewed periodically and the effects of revisions are reflected
in the financial statements in the period they are determined to be necessary.
Actual results could differ from these estimates.
Cash and cash equivalents
Cash and cash equivalents consist of short term, highly liquid investments, with
original maturities of less than three months when purchased and are stated at
cost. Interest is accrued as earned.
Property, Plant and Equipment
Property, plant and equipment are stated at cost less accumulated depreciation.
Depreciation is provided on the straight-line method over the estimated useful
lives of the various asset classes. Estimated lives are 5 years for laboratory
equipment; 3 years for computer equipment; 7 years for furniture and fixtures;
and the life of the lease for leasehold improvements. Maintenance, repairs and
minor replacements are charged to expense as incurred. Upon retirement or
disposal of assets, the cost and related accumulated depreciation are removed
from the Balance Sheet and any gain or loss is reflected in the Statement of
Operations.
Revenue Recognition
The Company recognizes revenue from contract research and development and
research payments in accordance with SEC Staff Accounting Bulletin No. 104,
Revenue Recognition, ("SAB 104"). In accordance with SAB 104, revenue is
recognized when persuasive evidence of an arrangement exists, delivery has
occurred, the fee is fixed and
41
determinable, collectibility is reasonably assured, contractual obligations have
been satisfied and title and risk of loss have been transferred to the customer.
The Company recognizes revenue from non-refundable up-front payments, not tied
to achieving a specific performance milestone, over the period which the Company
is obligated to perform services or based on the percentage of costs incurred to
date, estimated costs to complete and total expected contract revenue. Payments
for development activities are recognized as revenue as earned, over the period
of effort. Substantive at-risk milestone payments, which are based on achieving
a specific performance milestone, are recognized as revenue when the milestone
is achieved and the related payment is due, providing there is no future service
obligation associated with that milestone. In situations where the Company
receives payment in advance of the performance of services, such amounts are
deferred and recognized as revenue as the related services are performed.
For the years ended December 31, 2004, 2003 and 2002, revenues from National
Institute of Health ("NIH") SBIR grants approximated 77%, 54% and 78%,
respectively, of total revenues recognized by the Company.
Accounts Receivable
Accounts receivable are recorded net of provisions for doubtful accounts. An
allowance for doubtful accounts is based on specific analysis of the
receivables. At December 31, 2004, 2003 and 2002 the Company had no allowance
for doubtful accounts.
Research and development
Research and development expenses include costs directly attributable to the
conduct of research and development programs, including employees related costs,
materials, supplies, depreciation on and maintenance of research equipment, the
cost of services provided by outside contractors, and facility costs, such as
rent, utilities, and general support services. All costs associated with
research and development are expensed as incurred. Costs related to the
acquisition of technology rights, for which development work is still in
process, and that have no alternative future uses, are expensed as incurred.
Goodwill
Goodwill is recorded when the purchase price paid for an acquisition exceeds the
estimated fair value of the net identified tangible and intangible assets
acquired.
The Company performs an annual review in the fourth quarter of each year, or
more frequently if indicators of potential impairment exist, to determine if the
carrying value of the recorded goodwill is impaired. Goodwill impairment is
determined using a two-step approach in accordance with Statement of Financial
Accounting Standards No. 142 "Goodwill and Other Intangible Assets" ("SFAS
142"). The impairment review process compares the fair value of the reporting
unit in which goodwill resides to its carrying value. In 2004, the Company
operated as one business and one reporting unit. Therefore, the goodwill
impairment analysis was performed on the basis of the Company as a whole, using
the market capitalization of the Company as an estimate of its fair value. The
estimated fair values might produce significantly different results if other
reasonable assumptions and estimates were to be used.
Identified Intangible Assets
Acquisition-related intangible assets include acquired technology, customer
contracts, grants and covenants not to compete, and are amortized on a straight
line basis over periods ranging from 3.5-4 years.
In accordance with Statement of Financial Accounting Standards No. 144
"Accounting for the Impairment or Disposal of Long-Lived Assets" ("SFAS 144"),
the Company performs a review of its identified intangible assets to determine
if facts and circumstances exist which indicate that the useful life is shorter
than originally estimated or that the carrying amount of assets may not be
recoverable. If such facts and circumstances do exist, the Company assesses the
recoverability of identified intangible assets by comparing the projected
undiscounted net cash flows associated with the related asset or group of assets
over their remaining lives against their respective carrying amounts.
Impairment, if any, is based on the excess of the carrying amount over the fair
value of those assets. Changes in events or circumstances that may affect
long-lived assets include, but are not limited to, cancellations or terminations
of research contracts or pending government grants (Note 4).
42
Income taxes
Income taxes are accounted for under the asset and liability method prescribed
by Statement of Financial Accounting Standards No. 109, "Accounting for Income
Taxes." Deferred income taxes are recorded for temporary differences between
financial statement carrying amounts and the tax basis of assets and
liabilities. Deferred tax assets and liabilities reflect the tax rates expected
to be in effect for the years in which the differences are expected to reverse.
A valuation allowance is provided if it is more likely than not that some or all
of the deferred tax asset will not be realized.
Net loss per common share
The Company computes, presents and discloses earnings per share in accordance
with SFAS 128 "Earnings Per Share" ("EPS") which specifies the computation,
presentation and disclosure requirements for earnings per share of entities with
publicly held common stock or potential common stock. The statement defines two
earnings per share calculations, basic and diluted. The objective of basic EPS
is to measure the performance of an entity over the reporting period by dividing
income (loss) by the weighted average shares outstanding. The objective of
diluted EPS is consistent with that of basic EPS, that is to measure the
performance of an entity over the reporting period, while giving effect to all
dilutive potential common shares that were outstanding during the period. The
calculation of diluted EPS is similar to basic EPS except the denominator is
increased for the conversion of potential common shares.
The Company incurred losses for the years ended December 31, 2004, 2003 and 2002
and as a result, certain equity instruments are excluded from the calculation of
diluted loss per share. At December 31, 2004, 2003 and 2002, 68,038, 81,366 and
410,760 shares, respectively, of the Company's Series A convertible preferred
stock have been excluded from the computation of diluted loss per share as they
are anti-dilutive. At December 31, 2004, 2003 and 2002, outstanding options to
purchase 9,762,061, 6,460,811 and 5,807,561 shares, respectively, of the
Company's common stock with exercise prices ranging from $1.00 to $5.50 have
been excluded from the computation of diluted loss per share as they are
anti-dilutive. At December 31, 2004, 2003 and 2002, outstanding warrants to
purchase 8,469,594, 6,329,616 and 4,675,144 shares, respectively, of the
Company's common stock, with exercise prices ranging from $1.00 to $3.63 have
been excluded from the computation of diluted loss per share as they are
anti-dilutive.
Fair value of financial instruments
The carrying value of cash and cash equivalents, accounts payable and accrued
expenses approximates fair value due to the relatively short maturity of these
instruments.
Concentration of credit risk
The Company has cash in bank accounts that exceed the Federal Deposit Insurance
Corporation insured limits. The Company has not experienced any losses on its
cash accounts. No allowance has been provided for potential credit losses
because management believes that any such losses would be minimal.
Stock compensation
The Company applies the recognition and measurement principles of Accounting
Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees"
("APB 25") and related interpretations in accounting for its stock-based
compensation program. Accordingly, employees' and directors' related
compensation expense is recognized only to the extent of the intrinsic value of
the compensatory options or shares granted.
43
The following table illustrates the effect on net income (loss) available to
common stockholders and earnings (loss) per share as if the Company had applied
the fair value recognition provisions of SFAS No. 123, "Accounting for
Stock-Based Compensation" ("SFAS 123"), as amended by SFAS 148, "Accounting for
Stock-Based Compensation - Transaction and Disclosure, an amendment to FASB
Statement No. 123."
Year Ended December 31,
2004 2003 2002
------------ ------------ ------------
Net loss applicable to common shareholders, as reported .... ($9,373,319) ($5,276,640) ($3,360,227)
============ ============ ============
Add: Stock-based employee compensation expense
recorded under APB No. 25 .................................. -- -- 35,583
Deduct: Total stock-based employee compensation
expense determined under fair value based method for
all awards, net of related tax effects ..................... (1,105,330) (687,766) (153,882)
------------ ------------ ------------
Pro forma net loss applicable to common shareholders ....... ($10,478,649) ($5,964,406) ($3,478,526)
============ ============ ============
Net loss per share:
Basic and diluted -as reported ............................. $(0.40) $(0.34) $(0.32)
============ ============ ============
Basic and diluted -pro forma ............................... $(0.44) $(0.38) $(0.33)
============ ============ ============
The fair value of the options granted to employees during 2004, 2003 and 2002
ranged from $0.09 to $2.75 on the date of the respective grant using the
Black-Scholes option-pricing model.
The value of options granted in 2004, 2003 and 2002 was estimated at the date of
grant using the following weighted average assumptions:
2004 2003 2002
------------- ------------- ------------
Expected life 2 - 5 Yrs 3 - 5 Yrs 3 - 5 Yrs
Risk free interest rate 2.75% - 3.80% 2.89% - 3.24% 2.87% - 4.5%
Volatility 74% - 107% 100% 100%
Dividend yield 0% 0% 0%
Segment information
The Company is managed and operated as one business. The entire business is
managed by a single management team that reports to the chief executive officer.
The Company does not operate separate lines of business or separate business
entities with respect to any of its product candidates. Accordingly, the Company
does not prepare discrete financial information with respect to separate product
areas or by location and only has one reportable segment as defined by SFAS No.
131, "Disclosures about Segments of an Enterprise and Related Information".
Recent accounting pronouncements
In December 2004, the FASB issued SFAS No. 123R, "Share-Based Payment." SFAS No.
123R requires employee stock options and rights to purchase shares under stock
participation plans to be accounted for under the fair value method, and
eliminates the ability to account for these instruments under the intrinsic
value method prescribed by APB Opinion No. 25, and allowed under the original
provisions of SFAS No. 123. SFAS No. 123R requires the use of an option pricing
model for estimating fair value, which is amortized to expense over the service
periods. The requirements of SFAS No. 123R are effective for fiscal periods
beginning after June 15, 2005. SFAS No. 123R allows for either prospective
recognition of compensation expense or retrospective recognition, which may be
back to the original issuance of SFAS No. 123 or only to interim periods in the
year of adoption. The Company is currently evaluating these transition methods.
In March 2004, the Emerging Issues Task Force issued EITF 03-06, "Participating
Securities and the Two-Class Method under FASB Statement No. 128". This
statement provides additional guidance on the calculation and disclosure
requirements for earnings per share. The FASB concluded in EITF 03-06 that
companies with multiple
44
classes of common stock or participating securities, as defined by SFAS No. 128,
calculate and disclose earnings per share based on the two-class method. The
adoption of this statement did not have an impact on the Company's financial
statements presentation as the Company is in a loss position.
3. Business Acquisitions and Other Transactions
Purchase of Intangible Assets
In August 2004, the Company acquired certain government grants and two early
stage antiviral programs, Smallpox and Arenavirus, targeting certain agenda of
biological warfare for a purchase price of $1,000,000 in cash and 1,000,000
shares of the Company's common stock from ViroPharma Incorporated ("ViroPharma")
(the "ViroPharma Transaction"). Each program is in the early stage of
development and the Company expects both programs to be completed in or by 2006.
The shares issued to ViroPharma were valued at the closing date price.
The total purchase price of approximately $2.5 million was allocated to the
acquired government grants ($1.9 million) and to purchased in-process research
and development ($464,000 allocated to the Smallpox program and approximately
$104,000 to the Arenavirus program) ("IPRD"). The grants are amortized over the
contractual life of each grant or 2 years. The amount expensed as IPRD was
attributed to technology that has not reached technological feasibility and has
no alternate future use. The value allocated to IPRD was determined using the
income approach that included an excess earnings analysis reflecting the
appropriate costs of capital for the purchase. Estimates of future cash flows
related to the IPRD were made for both the Smallpox and Arenavirus programs. The
aggregate discount rate of approximately 55% utilized to discount the programs'
cash flows were based on consideration of the Company's weighted average cost of
capital as well as other factors, including the stage of completion and the
uncertainty of technology advances for these programs. If the programs are not
successful or completed in a timely manner, the Company's product pricing and
growth rates may not be achieved and the Company may not realize the financial
benefits expected from the programs.
Business Acquisition
On May 23, 2003, the Company acquired substantially all of the assets of Plexus
Vaccine Inc., ("Plexus") and assumed certain liabilities in exchange for
1,950,000 shares of the Company's common stock and 190,950 of the Company's
options and warrants at an exercise price of $1.62 per share. The results of
operations of Plexus have been included in the Statement of Operations of the
combined entity since May 23, 2003.
In determining the non-cash purchase price of Plexus, the equity consideration
has been calculated based on Emerging Issues Task Force ("EITF") No. 99-12,
"Accounting for Formula Arrangements under EITF 95-19". For this calculation,
the Company used the average market price for a few days before and after May
14, 2003, the announcement date. Based on EITF 99-12, the value of the common
stock issued was approximately $3,409,000. The value attributed to the options
and warrants exchanged was approximately $255,900. In addition, loans made to
Plexus, payments made on behalf of Plexus prior to the asset purchase agreement
and costs incurred for the transaction amounted to $406,030.
The allocation of the total purchase price of $4,070,903 is as follows:
Useful Life Fair Value
--------------- --------------
Equipment, net 3 - 7 years $ 27,711
Liabilities assumed N/A (494,142)
Acquired technology 10 years 2,191,000
Customer contract and grants 3 1/2 years 741,000
Covenant not to compete 3 1/2 years 707,000
Goodwill Indefinite 898,334
-----------
Purchase Price $ 4,070,903
===========
In May 2004, the Company sold certain intangible assets originally acquired from
Plexus, to Pecos Labs, Inc. ("Pecos"). See Note 4 "Intangible Assets".
45
Selected Unaudited Pro Forma Financial Information
The Company has prepared a condensed pro forma statement of operations in
accordance with SFAS 141, for the years ended December 31, 2003 and 2002 as if
Plexus were part of the Company as of January 1, 2003 and 2002, respectively.
Years Ended
December 31,
2003 2002
------------ ------------
Revenues $ 826,525 $ 516,828
Net loss $ (7,527,206) $ (5,398,730)
Net loss per common share - basic and diluted $ (0.46) $ (0.44)
Weighted average number of common shares outstanding 16,481,110 12,400,529
In the fourth quarter of 2003, a customer contract acquired with the acquisition
of Plexus was cancelled. Management recorded an impairment loss of $136,750,
included in the Company's operating expenses for the year ended December 31,
2003, to reflect the cancellation.
4. Intangible Assets
The following table presents the components of the Company's acquired intangible
assets with finite lives:
December 31, 2004 December 31, 2003
----------------------------------------- -----------------------------------------
Gross Gross
Carrying Accumulated Carrying Accumulated
Amount Amortization Net Amount Amortization Net
----------- ------------ ----------- ----------- ------------ -----------
Acquired grants $ 1,962,693 $ 327,118 $ 1,635,575 $ -- $ -- $ --
Customer contract and grants 83,571 19,499 64,072 604,250 128,772 475,478
Covenants not to compete 202,000 117,833 84,167 707,000 122,860 584,140
Acquired technology 330,483 -- 330,483 2,191,000 133,261 2,057,739
----------- ----------- ----------- ----------- ----------- -----------
$ 2,578,747 $ 464,450 $ 2,114,297 $ 3,502,250 $ 384,893 $ 3,117,357
----------- ----------- ----------- ----------- ----------- -----------
Amortization expense for intangible assets and costs included the following:
2004 2003
----------- -----------
Amortization of acquired grants $ 327,118 $ --
Amortization of customer contract and grants 89,344 128,772
Impairment of customer contract and grants 322,063 136,750
Amortization of covenants not to compete 196,972 122,860
Impairment of covenants not to compete 303,000 --
Amortization of acquired technology 219,100 133,261
Impairment of acquired technology 1,508,156 --
----------- -----------
$ 2,965,753 $ 521,643
----------- -----------
The Company anticipates amortization expense to approximate $1,182,000,
$767,500, $82,600, and $82,600 for the years ending December 31, 2005, 2006,
2007, and 2008, respectively.
Impairment of Intangible Assets
In December 2004, upon completion of the ViroPharma Transaction, integration of
the related acquired programs into the Company's operations, and the
demonstrated antiviral activity of the Company's lead smallpox compound against
several mouse models of poxvirus disease; management commenced an application
process for additional
46
government grants to support its continued efforts under the Smallpox and
Arenavirus antiviral programs. Management determined that significant efforts
and resources will be necessary to successfully continue the development efforts
under these programs and decided to allocate the necessary resources to support
its commitment. As a result, limited resources will be available for the
development of future product candidates that utilize the technology acquired
from Plexus in May 2003. These factors resulted in a significant reduction in
forecasted revenues related to that technology and a reduction in the future
remaining useful life, and triggered the related intangible asset impairment.
The amount of impairment recorded by management in December 2004 was determined
using the two-step process impairment review as required by SFAS 144. In the
first step, management compared the projected undiscounted net cash flows
associated with the technology acquired from Plexus over its remaining life
against its carrying amount. Management determined that the carrying amount of
the technology acquired from Plexus exceeded its projected undiscounted cash
flows. In the second step, management estimated the fair value of the technology
using the income method of valuation, which included the use of estimated
discounted cash flows using a discount rate of 28.5%. Based on management's
assessment, the Company recorded a non-cash impairment charge of approximately
$1.5 million in December 2004, which was included as a component of the
Company's operating loss.
Transfer of Intangible Assets to Pecos Labs, Inc.
In May 2004, the Company sold intangible assets from its immunological
bioinformatics technology and certain non-core vaccine development assets to a
privately-held company, Pecos Labs, Inc. ("Pecos") in exchange for 150,000
shares of Pecos common stock. In addition, concurrent with the asset transfer,
the Company terminated its employment agreement with the President of the
Company. The Company paid approximately $270,000 in severance to the President
as well as accelerated vesting on 100,000 stock options that were due to vest in
May 2004. No compensation charge was recorded as the exercise price of the
options was above the fair value market price on the date of termination. In
addition, the Company reduced the covenant not to compete with the President to
one year from the date of termination.
As a result of the Pecos transaction in the second quarter of 2004, the Company
performed an impairment review of the intangible assets in accordance with SFAS
144. The impairment of intangible assets consists of $307,063 of impairments to
unamortized intangible assets related to the grants transferred to Pecos and
$303,000 of impairment to the unamortized covenant not to compete with the
President of the Company due to the reduction of the covenant to one year from
the date of termination.
The Company is accounting for its investment in Pecos using the cost method
under Accounting Principles Board Opinion No. 18, "The Equity Method of
Accounting for Investments in Common Stock" based upon its 10% ownership of
Pecos. The Company valued the 150,000 common shares at $0.10 per share based on
an investment made at a concurrent time by an outside investor to Pecos at $0.10
per share.
5. Stockholders' Equity
At December 31, 2004, the Company's authorized share capital consisted of
60,000,000 shares, of which 50,000,000 are designated common shares and
10,000,000 are designated preferred shares. The Company's Board of Directors is
authorized to issue preferred shares in series with rights, privileges and
qualifications of each series determined by the Board.
2004 Placements
In August 2003, the Company entered into a securities purchase agreement with
MacAndrews & Forbes Holdings Inc. ("MacAndrews & Forbes"), a holding company of
which the Company's Chairman of the Board of Directors is Vice Chairman and a
director. Pursuant to the agreement, the Company raised gross proceeds of $1.0
million from MacAndrews & Forbes and certain of its employees, in exchange for
694,444 shares of the Company's common stock at a price of $1.44 per share and
warrants to purchase 347,222 shares of the Company's common stock at an exercise
price of $2.00 per share. In addition, MacAndrews & Forbes and certain of its
employees were granted an option, exercisable through October 13, 2003, to
invest up to an additional $9.0 million in the Company on the same terms.
47
In October 2003, MacAndrews & Forbes, certain of its employees and TransTech
Pharma, Inc., a related party to the Company and an affiliate of MacAndrews &
Forbes ("TransTech Pharma"), exercised their option to invest $9.0 million in
the Company, in exchange for an aggregate of 6,250,000 shares of common stock of
the Company's common stock, and warrants to purchase up to an aggregate of
3,125,000 shares of the Company's common stock at an exercise price of $2.00 per
share. Immediately prior to the exercise of such option, MacAndrews & Forbes
assigned the right to invest up to $5.0 million in the Company to TransTech
Pharma. The Company and TransTech Pharma are parties to a drug discovery
collaboration agreement signed in October 2002 (see Note 7).
In accordance with and subject to the terms and conditions of the securities
purchase agreement, MacAndrews & Forbes and certain of its employees invested
$2.2 million in exchange for 1,499,587 shares of the Company's common stock at a
price of $1.44 per share and received warrants to purchase up to an additional
749,794 shares of common stock at an exercise price of $2.00 per share.
In January 2004, following the approval of the Company's stockholders,
MacAndrews & Forbes and TransTech Pharma completed the final portion of their
investment. MacAndrews & Forbes invested $1,840,595 in exchange for 1,278,191
shares of common stock at a price of $1.44 per share, and warrants to purchase
up to an additional 639,095 shares of common stock at an exercise price of $2.00
per share; and TransTech Pharma invested $5,000,000 in exchange for 3,472,222
shares of common stock and warrants to purchase up to an additional 1,736,111
shares of common stock on the same terms. In addition, as part of the
investment, MacAndrews & Forbes and TransTech Pharma each were given the right
to appoint one board member to the Board of Directors, subject to certain terms
and conditions. On January 8, 2004, in accordance with the terms of the
investment, the respective designees of MacAndrews & Forbes and TransTech Pharma
were appointed to serve on SIGA's board of directors.
In 2004, the Company incurred costs of $161,000 related to work performed by
TransTech Pharma and its affiliates in connection with the DegP SBIR grant and
other grants.
2003 Placements
In June 2003, the Company raised gross proceeds of $1.5 million in a private
offering for 1,250,000 shares of common stock. In connection with the offering
the Company issued warrants to purchase 625,000 shares of the Company's common
stock to placement agents. Each of the warrants are exercisable at a price of
$2.00 per share and have a term of five years.
2002 Placements
In December 2002, the Company raised gross proceeds of $1.865 million in a
private offering of common stock and warrants to purchase the Company's common
stock. The Company sold 1,700,000 shares of common stock. In connection with the
offering the Company issued 171,216 warrants to purchase shares of the Company's
common stock to placement agents. The warrants are exercisable at a price of
$1.65 and have a term of five years. The Company received net proceeds of
$891,000 prior to December 31, 2002 and net proceeds of $791,940 after December
31, 2002. As such, as of December 31, 2002, the Company had recorded a
subscription receivable of $791,940.
In October 2002, the Company raised gross proceeds of $1.04 million in a private
offering of common stock and warrants to purchase the Company's common stock.
The Company sold 1,037,500 shares of common stock and 518,750 warrants. The
warrants are exercisable at $2.25 and have a term of five years. In connection
with the offering the Company issued 103,750 warrants to purchase shares of the
Company's common stock to placement agents. The warrants are exercisable at a
price of $1.50 and have a term of five years. The fair value of the warrants
attributable to consultants on the date of grant was approximately $64,670.
Other Transactions
In 2004, the Company reached a settlement agreement for breach of contract with
a founder of the Company, whereby the founder returned 40,938 common shares,
150,000 warrants and $15,000 to the Company. The common shares were retired by
the Company. The Company recorded the settlement amount as other income.
48
Preferred Stock
Holders of the Series A Convertible Preferred Stock are entitled to (i)
cumulative dividends at an annual rate of 6% payable when and if declared by the
Company's board of directors; (ii) in the event of liquidation of the Company,
each holder is entitled to receive $1.4375 per share (subject to certain
adjustments) plus all accrued but unpaid dividends; (iii) convert each share of
Series A to a number of fully paid and non-assessable shares of common stock as
calculated by dividing $1.4375 by the Series A Conversion Price (shall initially
be $1.4375); and (iv) vote with the holders of other classes of shares on an
as-converted basis.
During the years ended December 31, 2004 and 2003, certain preferred
stockholders converted 13,328 and 353,185 Series A convertible preferred stock
into 13,328 and 353,185, respectively, shares of common stock.
6. Stock option plan and warrants
Amended and Restated 1996 Incentive and Non-Qualified Stock Option Plan
In January 1996, the Company implemented its 1996 Incentive and Non-Qualified
Stock Option Plan (the "Plan"). The Plan as amended provides for the granting of
up to 10,000,000 shares of the Company's common stock to employees, consultants
and outside directors of the Company. The exercise period for options granted
under the Plan, except those granted to outside directors, is determined by a
committee of the Board of Directors. Stock options granted to outside directors
pursuant to the Plan must have an exercise price equal to or in excess of the
fair market value of the Company's common stock at the date of grant.
Stock option activity of the Company is summarized as follows:
Weighted Average
Number of Shares Exercise Price
Options outstanding on January 1, 2002 5,139,811 $ 2.50
Granted 777,750 2.66
Forfeited (85,000) 3.80
Exercised (25,000) 1.13
----------- -----------
Options outstanding at December 31, 2002 5,807,561 $ 2.52
Granted 813,250 1.79
Forfeited (160,000) 4.81
Exercised -- --
----------- -----------
Options outstanding at December 31, 2003 6,460,811 $ 2.33
Granted 3,442,500 1.34
Forfeited (138,334) 1.77
Exercised (2,916) 1.77
----------- -----------
Options outstanding at December 31, 2004 9,762,061 $ 1.99
=========== ===========
Options available for future grant at December 31, 2004 22,898
Weighted average fair value of options granted during 2004 $ 0.98
Weighted average fair value of options granted during 2003 $ 1.14
49
The following table summarizes information about options outstanding at December
31, 2004:
Number Weighted Average
Outstanding at Remaining Contractual Weighted Average Number Exercisable Weighted Average
Exercise Price December 31, 2004 Life (Years) Exercise Price at December 31, 2004 Exercise Price
1.00 - 1.85 4,586,584 8.98 $ 1.40 1,804,415 $ 1.47
2.00 - 2.75 4,837,250 6.19 $ 2.38 4,762,250 $ 2.38
3.94 - 5.5 338,227 4.16 $ 4.36 312,227 $ 4.39
------------ -----------
9,762,061 6,878,892
============ ===========
At December 31, 2004, options held outside of the plan included 125,000 options
granted to an employee and 125,000 options granted to consultants and have not
been included in the above tables.
The following tables summarize information about warrants outstanding at
December 31, 2004:
Weighted Average
Number of Warrants Exercise Price Expiration Dates
Outstanding at January 1, 2002 4,231,428 $ 3.61
Granted 793,716 2.03 09/30/2007 - 12/31/2007
Canceled / Expired (350,000) 7.32
------------------ ----------------
Outstanding at December 31, 2002 4,675,144 $ 3.06
Granted 2,161,250 1.98 12/31/2007 - 03/01/2012
Exercised (40,562) 1.19
Canceled / Expired (466,216) 5.83
------------------ ----------------
Outstanding at December 31, 2003 6,329,616 $ 2.50
Granted 2,375,206 2.00 08/10/2010
Exercised (85,228) 1.08
Canceled / Expired (150,000) 1.50
------------------ ----------------
Outstanding at December 31, 2004 8,469,594 $ 2.39
------------------ ----------------
Number of Warrants
Outstanding Exercise Price
568,410 1.45 - 1.69
5,349,972 2.00 - 2.25
2,551,212 2.94 - 3.63
------------------
8,469,594
==================
In February 2003, the Company entered into a 12-month consulting agreement with
an outside consultant in the amount of $249,420 to provide marketing research
support. Upon being awarded research contracts in excess of $2.0 million from
such support, the Company is obligated to issue 400,000 fully vested warrants at
an exercise price of $1.32 with an expiration of 3 years. As of December 31,
2004, the Company had not yet been awarded contracts in excess of $2.0 million.
In March 2004, the Company renewed the consulting agreement in the amount of
$320,000 for an additional eight months from March 1, 2004.
During 2003, the Company extended 3,225,000 options held by the Board of
Directors for an additional 5 years. The Company accounted for such extension in
accordance with Financial Accounting Standard Board Interpretation Number 44,
"Accounting for Certain Transactions Involving Stock Compensation - An
Interpretation of APB
50
Opinion Number 25". No compensation cost was incurred with the extension as the
exercise prices of the options were higher than the fair value of the common
stock at the date of modification.
2002 Grants
In September 2002, the Company entered into a four-month consulting agreement
under which a consultant assisted the Company with public relations efforts in
the United States and Europe in exchange for a monthly retainer of $3,500 for
the four-month term and 50,000 fully vested options to purchase shares of the
Company's common stock. Of the amount of fully vested options, 25,000 shares
have an exercise price of $1.50 per share and 25,000 shares have an exercise
price of $1.75. Upon grant, the Company recorded a $31,618 stock compensation
charge to operations based upon the fair value of the options.
In April 2002, in connection with an existing consulting agreement, the Company
granted a consultant an option to purchase 15,000 shares of the Company's common
stock under the Plan. Upon grant, the Company recorded a $10,269 stock
compensation charge to operations based upon the fair value of the option.
In connection with the development of its licensed technologies the Company
entered into a consulting agreement with a scientist who developed such
technologies, under which the consultant serves as the Company's Chief
Scientific Advisor. In June 2001, the Company entered into an amended consulting
agreement with the scientist under which the scientist was to provide services
to the Company for a three-year period commencing on September 10, 2001. In
consideration for the consulting services the scientist was to be paid an annual
fee of $50,000 payable quarterly. In addition, the Company granted the scientist
options to purchase 225,000 shares of common stock at $3.94 per share. On
September 10, 2001, ten percent of the options vested and the remaining options
were to vest in 36 monthly installments beginning on October 10, 2001. In
September 2002, the Company and the consultant terminated their arrangement and
all unvested options were forfeited. For the year ended December 31, 2002, the
Company recorded a stock compensation charge of $58,904.
7. Related Parties
Directors
The Company's Chairman of the Board of Directors is Vice Chairman and a director
of MacAndrews & Forbes. During 2003 and January 2004, MacAndrews & Forbes, along
with TransTech Pharma, invested $10.0 million in SIGA. Furthermore, two
directors of the Company are also directors of TransTech Pharma. Additionally, a
director of the Company, is a member of the Company's outside counsel. (See Note
5).
Collaborative Research Agreements
In October 2002, the Company entered into a collaborative research agreement
with TransTech Pharma, a related party, for the discovery and treatment of human
diseases. Under the terms of the agreement, TransTech Pharma and the Company
have agreed to contribute each of their respective services and share equally in
costs of specified research projects. In consideration of the services performed
by TransTech Pharma and use of its proprietary technology, SIGA granted an
exclusive, fully-paid, nontransferable, nonsublicenseable, limited license to
use existing rights to patents and technologies. Both parties will share equally
in the ownership of compounds and related intellectual property derived from
such research efforts. In January 2004, TransTech Pharma invested $5.0 million
in SIGA (See Note 5).
51
8. Property, Plant and Equipment
Property, plant and equipment consisted of the following at December 31, 2004
and 2003:
Laboratory equipment $ 1,259,711 $ 1,134,110
Leasehold improvements 632,435 690,138
Computer equipment 212,077 199,209
Furniture and fixtures 194,890 292,817
Construction in-progress 163,397 --
------------ ------------
2,462,510 2,316,274
Less - Accumulated depreciation (1,954,495) (1,937,228)
------------ ------------
Property, plant & equipment, net $ 508,015 $ 379,046
============ ============
9. Income Taxes
The Company has incurred losses since inception, which have generated net
operating loss carryforwards of approximately $31,350,000 at December 31, 2004
for federal and state income tax purposes. These carryforwards are available to
offset future taxable income and begin expiring in 2010 for federal income tax
purposes. As a result of a previous change in stock ownership, the annual
utilization of the net operating loss carryforwards is subject to limitation.
The net operating loss carryforwards and temporary differences, arising
primarily from deferred research and development expenses and differences in the
treatment of intangible assets, result in a noncurrent deferred tax asset at
December 31, 2004 and 2003 of approximately $16,500,000 and $13,030,000,
respectively. In consideration of the Company's accumulated losses and the
uncertainty of its ability to utilize this deferred tax asset in the future, the
Company has recorded a valuation allowance of an equal amount on such date to
fully offset the deferred tax asset.
Following is a summary of changes in our valuation allowance for deferred tax
assets as of and for the years ended December 31, 2004, 2003 and 2002 (in
thousands):
Additions
Balance at Charged to Costs Balance at
December 31, Beginning of Year and Expenses Deductions End of Year
------------------ ------------------ -------------- ---------------
2004 $ 13,030 $ 3,470 $ -- $ 16,500
2003 $ 11,144 $ 1,886 $ -- $ 13,030
2002 $ 9,811 $ 1,333 $ -- $ 11,144
For the years ended December 31, 2004 and 2003, the Company's effective tax rate
differs from the federal statutory rate principally due to net operating losses
and other temporary differences for which no benefit was recorded, state taxes
and other permanent differences.
10. Commitments and Contingencies
Employment agreements
In July 2004, the Company entered into a 3-year employment agreement with its
Vice President of Business Development, commencing in August 2004. The
employment agreement provides for an annual salary of $230,000 plus bonuses
based on certain objectives and goals. Under the agreement, the Company granted
the employee an option to acquire 200,000 shares of its common stock at an
exercise price of $1.40, of which 50,000 options vested upon signing and 50,000
vests at each of the next 3 anniversaries. At the discretion of the Board of
Directors the employee may be granted additional awards of up to 25,000 shares
each, upon meeting certain milestones. The agreement has a one year renewal
option.
52
In July 2004, the Company entered into an employment agreement with Bernard L.
Kasten, M.D. to serve as the Company's Chief Executive Officer ("CEO"). The
employment agreement provides for an annual salary of $250,000 plus, at the
discretion of the Board of Directors, bonus payments for a 3-year initial term
with an automatic 3-year renewal unless either party gives notice that it does
not want to renew. The agreement also provides for an award of 2,500,000 options
to purchase common stock with an exercise price of $1.30, of which 500,000
vested upon signing, one million options vest over the 3-year initial term and
the remaining 1 million options vest over the renewal term. The CEO is also
entitled to additional options, to be granted upon meeting certain milestones.
In July 2004, the Company entered into an amendment to its existing employment
agreement with the Company's Chief Scientific Officer. Pursuant to the
amendment, the employment agreement is effective through December 31, 2007 and
provides for an annual salary of $225,000 plus, at the discretion of the Board
of Directors, a bonus not to exceed 50% of the Chief Scientific Officer's
salary. The agreement also provides for an option grant of 150,000 options to
purchase common stock with an exercise price of $1.40, of which 75,000 vest on
December 31, 2005 and 75,000 vest on December 31, 2006. In October 2002, the
Company granted the CSO options to acquire 300,000 shares of the Company's
common stock at an exercise price of $2.50. Upon such grant, the CSO was
required to surrender 50,000 shares granted under a previous grant with an
exercise price of $3.94. Under the October 2002 grant, 75,000 shares vested
immediately, 75,000 shares vested on September 1, 2003 and 2004 and 75,000
shares will vest on September 1, 2005. As such, 50,000 options are considered
variable options under APB 25 as replacement awards for the options surrendered.
For the years ended December 31, 2004, 2003 and 2002, there was no stock
compensation charge as the fair value of the underlying common stock was below
the exercise price of the option.
In June 2004, the Company entered into an amendment to its existing employment
agreement with the Company's Chief Financial Officer. Pursuant to the amendment,
the employment agreement is effective through December 31, 2005 and provides for
an annual salary of $230,000 plus a one-time payment of $50,000 for the Chief
Financial Officer's prior service as Acting Chief Executive Officer. An
additional bonus not to exceed 25% of the Chief Financial Officer's salary may
be awarded at the discretion of the Board of Directors. The agreement also
provides for an option grant of 150,000 options to purchase common stock with an
exercise price of $1.40, of which 75,000 vested upon signing and the remainder
to vest on a prorata basis from January 1, 2005 through December 31, 2005.
In May 2003, the President and CEO of Plexus Vaccine was appointed President of
SIGA. The President and the Company entered into an employment agreement for the
period of May 23, 2003 until December 31, 2005. Under the agreement,
compensation was set at an annual minimum base salary of $216,000 with certain
benefits, as defined. Additionally, 300,000 options were granted under the Plan
at an exercise price of $1.81 per share. Of such grant, 100,000 options vested
immediately, 100,000 options were scheduled to vest in May 2004 and the
remaining 100,000 options were scheduled to vest in May 2005. In May 2004, upon
selling intangible assets from the Company's immunological bioinformatics
technology and certain non-core vaccine development assets to Pecos, the Company
terminated its employment agreement with its President. The Company paid
approximately $270,000 in severance to the President as well as accelerated
vesting on 100,000 stock options that were due to vest in May 2004. No
compensation charge was recorded as the exercise price of the options was above
the fair value market price on the date of termination.
Operating lease commitments
The Company leases certain facilities and office space under operating leases.
Rent expense for the years ended December 31, 2004, 2003 and 2002 was
approximately $297,000, $235,000 and $213,000, respectively. Minimum future
rental commitments under operating leases having noncancelable lease terms in
excess of one year are as follows:
53
Year ended December 31,
2005 $ 239,700
2006 255,400
2007 261,800
2008 133,200
2009 135,900
2010 22,700
-----------
Total $ 1,048,700
===========
Other
From time to time, the Company is involved in disputes or legal proceedings
arising in the ordinary course of business. The Company believes that there is
no dispute or litigation pending that could have, individually or in the
aggregate, a material adverse effect on its financial position, results of
operations or cash flows.
54
11. Financial Information By Quarter (Unaudited) (in thousand, except for per
share data)
2004 For The Quarter Ended March 31, June 30, September 30, December 31,
------------ ------------ -------------- --------------
Revenues $ 161 $ 299 $ 533 $ 846
Selling, general & administrative $ 1,006 $ 1,112 $ 919 $ 1,005
Research and development $ 1,020 $ 1,026 $ 827 $ 1,292
Patent preparation fees $ 92 $ 55 $ 84 $ 162
In-process research and development $ -- $ -- $ 568 $ --
Impairment of intangible assets $ -- $ 610 $ -- $ 1,508
Operating loss $ 1,956 $ 2,504 $ 1,865 $ 3,123
Net loss $ 1,940 $ 2,490 $ 1,837 $ 3,106
Net loss per share: basic and diluted $ 0.08 $ 0.11 $ 0.08 $ 0.13
Market price range for common stock
High $ 2.34 $ 1.93 $ 1.63 $ 1.75
Low $ 1.85 $ 1.29 $ 1.23 $ 1.35
2003 For The Quarter Ended March 31, June 30, September 30, December 31,
------------ ------------ -------------- --------------
Revenues $ 205 $ 244 $ 176 $ 107
Selling, general & administrative $ 560 $ 748 $ 684 $ 654
Research and development $ 477 $ 643 $ 1,001 $ 822
Patent preparation fees $ 56 $ 66 $ 65 $ 113
In-process research and development $ -- $ -- $ -- $ --
Impairment of intangible assets $ -- $ -- $ -- $ 137
Operating loss $ 889 $ 1,214 $ 1,574 $ 1,619
Net loss $ 882 $ 1,211 $ 1,571 $ 1,613
Net loss per share: basic and diluted $ 0.07 $ 0.09 $ 0.09 $ 0.09
Market price range for common stock
High $ 1.49 $ 1.91 $ 2.13 $ 2.60
Low $ 1.02 $ 1.09 $ 1.61 $ 1.80
55
Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure
None.
Item 9A. Controls and Procedures
As of the end of the period covered by this Annual Report on Form 10-K,
the Company's management, including the Chief Executive Officer and Chief
Financial Officer, carried out an evaluation of the effectiveness of the
Company's disclosure controls and procedures. Based upon that evaluation, the
Chief Executive Officer and Chief Financial Officer have concluded that the
Company's disclosure controls and procedures are effective.
There have been no changes in the Company's internal controls over
financial reporting identified in connection with the evaluation by the Chief
Executive Officer and Chief Financial Officer that occurred during the Company's
fourth fiscal quarter that has materially affected, or is reasonably likely to
materially affect, the Company's internal control over financial reporting.
Item 9B. Other Information
None.
56
PART III
Item 10. Directors and Executive Officers of the Registrant
Information required by this item is incorporated by reference from our
Proxy Statement for the 2005 Annual Meeting of Shareholders.
Item 11. Executive Compensation
Information required by this item is incorporated by reference from our
Proxy Statement for the 2005 Annual Meeting of Shareholders.
Item 12. Security Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters
Information required by this item is incorporated by reference from our
Proxy Statement for the 2005 Annual Meeting of Shareholders.
Item 13. Certain Relationships and Related Transactions
Information required by this item is incorporated by reference from our
Proxy Statement for the 2005 Annual Meeting of Shareholders.
Item 14. Principal Accountant Fees and Services
Information required by this item is incorporated by reference from our
Proxy Statement for the 2005 Annual Meeting of Shareholders.
57
PART IV
Item 15. Exhibits
Exhibit
No. Description
- ------- -----------
2(a) Asset Purchase Agreement, dated as of May 14, 2003, between the
Company and Plexus Vaccine Inc. (Incorporated by reference to Form
8-K of the Company filed June 9, 2003).
3(a) Restated Articles of Incorporation of the Company (Incorporated by
reference to Form S-3 Registration Statement of the Company dated
May 10, 2000 (No. 333-36682)).
3(b) Bylaws of the Company (Incorporated by reference to Form SB-2
Registration Statement of the Company dated March 10, 1997 (No.
333-23037)).
3(c) Certificate of Designations of Series and Determination of Rights
and Preferences of Series A Convertible Preferred Stock of the
Company dated July 2, 2001 (Filed with the Company's Annual Report
on Form 10-KSB for the year ended December 31, 2002 initially filed
with the Securities and Exchange Commission on March 31, 2003).
4(a) Form of Common Stock Certificate (Incorporated by reference to Form
SB-2 Registration Statement of the Company dated March 10, 1997 (No.
333-23037)).
4(b) Warrant Agreement dated as of September 15, 1996 between the Company
and Vincent A. Fischetti (1) (Incorporated by reference to Form SB-2
Registration Statement of the Company dated March 10, 1997 (No.
333-23037)).
4(c) Warrant Agreement dated as of November 18, 1996 between the Company
and David de Weese (1) (Incorporated by reference to Form SB-2
Registration Statement of the Company dated March 10, 1997 (No.
333-23037)).
4(d) Warrant Agreement between the Company and Stefan Capital, dated
September 9, 1999 (Incorporated by reference to the Company's Annual
Report on Form 10-KSB for the year ended December 31, 1999).
4(e) Registration Rights Agreement, dated as of May 23, 2003, between the
Company and Plexus Vaccine Inc. (Incorporated by reference to Form
8-K of the Company filed June 9, 2003).
4(f) Registration Rights Agreement, dated as of August 13, 2003, between
the Company and MacAndrews & Forbes Holdings Inc. (Incorporated by
reference to Form 8-K of the Company filed August 18, 2003).
10(a) License and Research Support Agreement between the Company and The
Rockefeller University, dated as of January 31, 1996; and Amendment
to License and Research Support Agreement between the Company and
The Rockefeller University, dated as of October 1, 1996(2)
(Incorporated by reference to Form SB-2 Registration Statement of
the Company dated March 10, 1997 (No. 333-23037)).
10(b) Research Agreement between the Company and Emory University, dated
as of January 31, 1996(2) (Incorporated by reference to Form SB-2
Registration Statement of the Company dated March 10, 1997 (No.
333-23037)).
10(c) Research Support Agreement between the Company and Oregon State
University, dated as of January 31, 1996(2) (Incorporated by
reference to Form SB-2 Registration Statement of the Company dated
March 10, 1997 (No. 333-23037)). Letter Agreement dated as of March
5, 1999 to continue the Research Support Agreement (Incorporated by
reference to the Company's Annual Report on Form 10-KSB for the year
ended December 31, 1999).
58
10(d) Option Agreement between the Company and Oregon State University,
dated as of November 30, 1999 and related Amendments to the
Agreement (Incorporated by reference to the Company's Annual Report
on Form 10-KSB for the year ended December 31, 1999).
10(e) Employment Agreement between the Company and Dr. Kevin F. Jones,
dated as of January 1, 1996 (Incorporated by reference to Form SB-2
Registration Statement of the Company dated March 10, 1997 (No.
333-23037)).
10(f) Employment Agreement between the Company and David de Weese, dated
as of November 18, 1996(1) (Incorporated by reference to Form SB-2
Registration Statement of the Company dated March 10, 1997 (No.
333-23037)).
10(g) Employment Agreement between the Company and Dr. Dennis Hruby, dated
as of April 1, 1997 (Incorporated by reference to Amendment No. 1 to
Form SB-2 Registration Statement of the Company dated July 11, 1997
(No. 333-23037)).
10(h) Clinical Trials Agreement between the Company and National Institute
of Allergy and Infectious Diseases, dated as of July 1, 1997
(Incorporated by reference to Amendment No. 1 to Form SB-2
Registration Statement of the Company dated July 11, 1997 (No.
333-23037)).
10(i) Research Agreement between the Company and The Research Foundation
of State University of New York, dated as of July 1, 1997(2)
(Incorporated by reference to Amendment No. 1 to Form SB-2
Registration Statement of the Company dated July 11, 1997 (No.
333-23037)).
10(j) Collaborative Research and License Agreement between the Company and
Wyeth, dated as of July 1, 1997(2) (Incorporated by reference to
Amendment No. 3 to Form SB-2 Registration Statement of the Company
dated September 2, 1997 (No. 333-23037)).
10(k) Research Collaboration and License Agreement between the Company and
The Washington University, dated as of February 6, 1998 (2)
(Incorporated by reference to the Company's Annual Report on Form
10-KSB for the year ended December 31, 1997).
10(l) Settlement Agreement and Mutual Release between the Company and The
Washington University, dated as of February 17, 2000 (Incorporated
by reference to the Company's Annual Report on Form 10-KSB for the
year ended December 31, 1999).
10(m) Technology Transfer Agreement between the Company and MedImmune,
Inc., dated as of February 10, 1998 (Incorporated by reference to
the Company's Annual Report on Form 10-KSB for the year ended
December 31, 1997).
10(n) Employment Agreement between the Company and Dr. Dennis Hruby, dated
as of January 1, 1998 (Incorporated by reference to the Company's
Annual Report on Form 10-KSB for the year ended December 31, 1997).
Amendment to the Agreement, dated as of October 15, 1999
(Incorporated by reference to the Company's Annual Report on Form
10-KSB for the year ended December 31, 1999). Amendment to the
Agreement dated as of June 12, 2000. Amendment to the Agreement,
dated as of January 31, 2002 (Incorporated by reference to the
Company's Annual Report on Form 10-KSB for the year ended December
31, 2001). Amendment to the Agreement, dated October 1, 2002 (Filed
with the Company's Annual Report on Form 10-KSB for the year ended
December 31, 2002 initially filed with the Securities and Exchange
Commission on March 31, 2003). Amendment to the Agreement, dated as
of July 29, 2004 (Incorporated by reference to the Company's
Quarterly Report on Form 10QSB for the quarter ended September 30,
2004).
10(o) Employment Agreement between the Company and Thomas Konatich, dated
as of April 1, 1998 (Incorporated by reference to the Company's
Annual Report on Form 10-KSB for the year ended December 31, 1997).
Extension and Amendment of the Agreement, dated as of January 19,
2000
59
(Incorporated by reference to the Company's Annual Report on Form
10-KSB for the year ended December 31, 1999). Amendment and
Restatement of the Agreement, dated as of October 6, 2000
(Incorporated by reference to the Company's Annual Report on Form
10-KSB for the year ended December 31, 2000). Amendment and Waiver
to the Agreement, dated as of January 31, 2002 (Incorporated by
reference to the Company's Annual Report on Form 10-KSB for the year
ended December 31, 2001). Amendment to the Agreement, dated November
5, 2002 (Filed with the Company's Annual Report on Form 10-KSB for
the year ended December 31, 2002 initially filed with the Securities
and Exchange Commission on March 31, 2003). Amendment to Amended and
Restated Agreement, dated as of July 29, 2004 (Incorporated by
reference to the Company's Quarterly Report on Form 10QSB for the
quarter ended September 30, 2004).
10(p) Option Agreement between the Company and Ross Products Division of
Abbott Laboratories, dated February 28, 2000 (Incorporated by
reference to the Company's Annual Report on Form 10-KSB for the year
ended December 31, 1999).
10(q) Agreement between the Company and Oregon State University for the
Company to provide contract research services to the University
dated September 24, 2000 (Incorporated by reference to the Company's
Annual Report on Form 10-KSB for the year ended December 31, 2000).
10(r) License and Research Agreements between the Company and the Regents
of the University of California dated December 6, 2000 (Incorporated
by reference to the Company's Annual Report on Form 10-KSB for the
year ended December 31, 2000).
10(s) Amended and Restated 1996 Incentive and Non-Qualified Stock Option
Plan dated August 15, 2001 (Incorporated by reference to the
Company's Annual Report on Form 10-KSB for the year ended December
31, 2001).
10(t) Small Business Innovation Grant to the Company from the National
Institutes of Health dated May 17, 2002 (Filed with the Company's
Annual Report on Form 10-KSB for the year ended December 31, 2002
initially filed with the Securities and Exchange Commission on March
31, 2003).
10(u) Research and License Agreement between the Company and TransTech
Pharma, Inc. dated October 1, 2002 (Filed with the Company's Annual
Report on Form 10-KSB for the year ended December 31, 2002 initially
filed with the Securities and Exchange Commission on March 31,
2003).
10(v) Retainer Agreement between the Company and Saggi Captial, Inc.,
dated November 1, 2002 (Filed with the Company's Annual Report on
Form 10-KSB for the year ended December 31, 2002 initially filed
with the Securities and Exchange Commission on March 31, 2003).
10(w) Retainer Agreement between the Company and Bridge Ventures, Inc.,
dated November 1, 2002 (Filed with the Company's Annual Report on
Form 10-KSB for the year ended December 31, 2002 initially filed
with the Securities and Exchange Commission on March 31, 2003).
10(x) Contract between the Company and the Department of the US Army dated
December 12, 2002 (Filed with the Company's Annual Report on Form
10-KSB for the year ended December 31, 2002 initially filed with the
Securities and Exchange Commission on March 31, 2003).
10(y) Contract between the Company and Four Star Group dated February 5,
2003 (Filed with the Company's Annual Report on Form 10-KSB for the
year ended December 31, 2002 initially filed with the Securities and
Exchange Commission on March 31, 2003).
10(z) Employment Agreement, dated as of May 23, 2003, between the Company
and Susan K. Burgess, Ph.D. (Incorporated by reference to Form 8-K
of the Company filed June 9, 2003).
60
10(aa) Securities Purchase Agreement, dated as of August 13, 2003, between
the Company and MacAndrews & Forbes Holdings Inc. (Incorporated by
reference to Form 8-K of the Company filed August 18, 2003).
10(bb) Letter Agreement dated October 8, 2003 among the Company, MacAndrews
& Forbes Holdings Inc. and TransTech Pharma, Inc. (Incorporated by
reference to Form 8-K of the Company filed August 18, 2003).
10(cc) Employment Agreement dated as of July 2, 2004, between the Company
and Bernard L. Kasten, M.D. (Incorporated by reference to the
Company's Quarterly Report on Form 10QSB for the quarter ended June
30, 2004).
10(dd) Employment Agreement, dated as of July 29, 2004, between the Company
and John Odden (Incorporated by reference to the Company's Quarterly
Report on Form 10QSB for the quarter ended September 30, 2004).
14 The Company's Code of Ethics and Business Conduct (Incorporated by
reference to the Company's Annual Report on Form 10-KSB for the year
ended December 31, 2003).
23.1 Consent of Independent Registered Public Accounting Firm.
31.1 Certification pursuant to Rules 13a-15(e) or 15d-15(e) under the
Securities Exchange Act of 1934, as adopted pursuant to Section 302
of the Sarbanes-Oxley Act of 2002 - Chief Executive Officer.
31.2 Certification pursuant to Rules 13a-15(e) or 15d-15(e) under the
Securities Exchange Act of 1934, as adopted pursuant to Section 302
of the Sarbanes-Oxley Act of 2002 - Chief Financial Officer.
32.1 Certification Pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - Chief
Executive Officer.
32.2 Certification Pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - Chief
Financial Officer.
- ----------
(1) These agreements were entered into prior to the reverse split of the
Company's Common Stock and, therefore, do not reflect such reverse split.
(2) Confidential information is omitted and identified by an * and filed
separately with the SEC with a request for Confidential Treatment.
61
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
SIGA TECHNOLOGIES, INC.
(Registrant)
Date: March 29, 2005 By: /s/ Bernard L. Kasten, M.D.
---------------------------
Bernard L. Kasten, M.D.
Chief Executive Officer
Pursuant to the requirements of the Securities Act of 1934, this report
has been signed below by the following persons on behalf of the registrant and
in the capacities and on the dates indicated.
Signature Title of Capacities Date
/s/ Bernard L. Kasten, M.D.
- ---------------------------------
Bernard L. Kasten, M.D. Chief Executive Officer March 29, 2005
/s/ Thomas N. Konatich
- ---------------------------------
Thomas N. Konatich Chief Financial Officer March 29, 2005
/s/ Donald G. Drapkin
- ---------------------------------
Donald G. Drapkin Chairman of the Board March 29, 2005
/s/ James J. Antal
- ---------------------------------
James J. Antal Director March 29, 2005
/s/ Thomas E. Constance
- ---------------------------------
Thomas E. Constance Director March 29, 2005
/s/ Adnan M. Mjalli, Ph.D.
- ---------------------------------
Adnan M. Mjalli, Ph.D. Director March 29, 2005
/s/ Mehmet C. Oz, M.D.
- ---------------------------------
Mehmet C. Oz, M.D. Director March 29, 2005
/s/ Eric A. Rose, M.D.
- ---------------------------------
Eric A. Rose, M.D. Director March 29, 2005
/s/ Paul G. Savas
- ---------------------------------
Paul G. Savas Director March 29, 2005
/S/ Judy S. Slotkin
- ---------------------------------
Judy S. Slotkin Director March 29, 2005
/s/ Michael Weiner, M.D.
- ---------------------------------
Michael Weiner, M.D. Director March 29, 2005